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ABSTRACT OF DISSERTATION

THERAPEUTIC POTENTIAL OF TARGETING REACTIVE OXYGEN SPECIES
(ROS) STRESS IN MYELODYSPLASTIC SYNDROME (MDS)
Myelodysplastic syndromes (MDS) are a diverse group of clonal
hematologic disorders characterized by ineffective blood cell production
(hematopoiesis), dysplastic (abnormal) cell morphology in one or more
hematopoietic lineages, and progression to acute myeloid leukemia (AML). The
response rate to current FDA approved therapies is low and not durable. Just
about 50% of MDS patients respond to these drug therapies and a majority of
responders relapse within 2-3 years. Hence there is a compelling need to
investigate new therapy options.
We investigated the anticancer potential and possible underlying
molecular mechanisms of action of a plant-derived compound, Withaferin A
(WFA) in MDS. We utilized the MDS-L cell line model to test the efficacy of WFA
both in vitro and in vivo. WFA exhibited potent but selective cytotoxicity to MDS-L
cells as seen by a dose-dependent decrease in cell viability of these cells when
treated with WFA whereas WFA had no apparent significant effect on the viability
of normal primary human bone marrow cells. In addition, WFA significantly
reduced engraftment of MDS-L cells in a xenotransplantation model. Through the
use of microarray gene expression analysis, we identified that reactive oxygen
species (ROS)-activated JNK/AP-1 signaling is a major pathway mediating
apoptosis of MDS-L cells by WFA. Increase in ROS plays a central role in the
cytotoxicity of WFA in MDS-L cells. Consistent with the finding that increase in
ROS plays a central role in mediating WFA cytotoxicity in MDS-L cells, WFA did
not increase ROS levels in normal bone marrow cells.
Taken together, these results suggest that pharmacologic manipulation of
redox biology could be exploited to selectively target malignant cells while
sparing normal cells in MDS.
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CHAPTER ONE
INTRODUCTION
Myelodysplastic syndromes (MDS) are a diverse group of clonal
hematologic disorders characterized by ineffective blood cell production
(hematopoiesis), dysplastic (abnormal) cell morphology in one or more
hematopoietic lineages, and progression to acute myeloid leukemia (AML)1,2.
Ineffective hematopoiesis leads to peripheral cytopenias such as anemia,
neutropenia and thrombocytopenia3; anemia being the most commonly
observed. In fact, more than 80% of MDS diagnosis are due to anemia-related
symptoms which can manifest as fatigue, exercise intolerance, dizziness,
cognitive impairment or an altered sense of well-being3,4. Although less common,
infection, easy bruising and bleeding are other clinical manifestations of MDS
that can prompt hematologic evaluation and diagnosis3. The peculiar clinical
phenotype of anemia in MDS is that it is chronic and worsens with time4. As a
result, most MDS patients become transfusion dependent over the course of the
disease5. Increased number and frequency of transfusions decreases overall
quality of life and has been associated with a proportional increase in mortality.
Organ complications from transfusion-related iron overload are thought to be
related to the observed decrease in overall survival in transfusion dependent
MDS patients4,5.
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CLINICAL FEATURES, PATHOGENESIS AND DIAGNOSIS OF MDS
Characteristic abnormal cell morphologies that can occur in MDS are
outlined in Table 1.1. MDS diagnosis heavily relies on these characteristic
morphologic changes3.

The pathogenesis of MDS is not clearly understood but the presence of
some healthy cells and involvement of both myeloid and lymphoid hematopoietic
2

cell lineages suggest that it is a clonal stem cell disease6. Hematopoietic cell
hierarchy and lineages are illustrated in Figure 1.1. Observed hematopoietic cell
defects in MDS span the gamut from reduced (erythrocyte, neutrophil,
thrombocyte, CD4 T cell and NK cell) or increased (thrombocyte and CD8 T cell)
numbers to defective function (phagocytosis, bactericidal activity, adhesion and
chemotaxis of granulocytes, and antibody production by B cells)3.

3

Some recent elegant studies have demonstrated the clonality and stem cell origin
in MDS by integrating cellular hierarchy and cancer genetics. Mutations
implicated in MDS occur in the stem cell compartment (founder clones) and new
mutations are acquired with disease progression to AML (daughter subclones)7,8.
The malignant cells are clonally derived since all mutations found in founder
clones were also present in the daughter subclones7,8. These studies suggest
that like most cancers, MDS pathogenesis involves a stepwise acquisition of
driver mutations through multiple cycles of mutation. Greater than 90% of MDS
cases are associated with one or more driver mutations and prognosis
significantly worsens with increase in driver mutations3,9. Genes involved in DNA
methylation (DNMT3A, TET2, IDH1/2), chromatin modification (EZH2, ASXL1),
transcriptional regulation (EVI1, RUNX1, GATA2) and RNA splicing (SF3B1,
U2AF1, SRSF2 and ZRSR2) are among the most commonly mutated genes9.
Several cytogenetic abnormalities observed in MDS are outlined in Table 1.2 and
are abnormalities used for presumptive diagnosis3.

4

MDS is one of the most challenging myeloid neoplasms to diagnose10.
Heterogeneity in the subtypes of MDS adds a layer of complexity to the
diagnostic process. The World Health Organization (WHO) classification system
classifies MDS into 7 subtypes (Table 1.3)10. This classification system is based
on a combination of morphology, immunophenotype and genetic features of
peripheral blood and bone marrow, and clinical features10.
5

In addition to the heterogeneity of MDS, differential diagnosis involves exclusion
of other conditions that may present with cytopenia and/or dysplasia such as
AML3. AML is of particular interest in the differential diagnosis of MDS because it
can occur as a continuum of disease with progression of MDS as the distinction
between the two diseases is largely based on blast percentage10. The WHO
6

recommends 20% blast cells as a cut off between MDS and AML10. MDS
diagnosis is based on the evaluation of peripheral blood and bone marrow
smears3. Chromosomal abnormalities play a crucial role in diagnosis as they
distinguish between MDS and AML and aid in the classification of MDS
subtypes10. Three main features (Table 1.4) which present in most cases of MDS
are used as guideline for diagnosis3.

EPIDEMIOLOGY, INCIDENCE AND PROGNOSIS OF MDS
MDS can occur de novo (classified as primary MDS) or after exposure to
potentially mutagenic therapy (classified as secondary therapy-related MDS) 11.
Therapy-related myelodysplastic syndrome (t-MDS) is thought to be a late
complication that can occur after cytotoxic therapy (chemotherapy, radiotherapy,
or both) for both malignant and non-malignant disease12-14. Although the
7

mechanism by which exposure to cytotoxic agents causes t-MDS remains
unknown, t-MDS is a well-recognized clinical syndrome that is included in the
classification of myeloid neoplasms by the World Health Organization
(WHO)10,12,14,15. Generally, 10-20% of diagnosed MDS cases are t-MDS16.
Median latency from the time of initial cytotoxic therapy to t-MDS diagnosis can
vary from 3 – 7 years13,14,17. MDS is thought to be a disease of the elderly as the
risk of MDS increases with age18. Reported median age of diagnosis varies by
study cohort from 65 – 76 years and incidence is slightly significantly higher in
males3,18-20. Therapy-related MDS on the other hand can occur at any age as
onset depends on the age of exposure to cytotoxic therapy14,21. Although rare,
pediatric MDS cases have also been reported22,23.
The incidence of MDS in the United States is not known but conservative
estimates suggest at least 30, 000 new cases occur annually18,24. Several
studies have demonstrated the actual incidence of MDS is likely higher than is
predicted from cancer registries24-26. This is in part because MDS only became a
reportable malignancy in 2001, long after the creation of the National Cancer
Institute (NCI) cancer surveillance program in 197324,27,28. Moreover, because
BM evaluation is required for definitive diagnosis, some cases go undiagnosed
especially in older individuals who usually have other comorbidities24,25. Survival
of MDS patients is generally very poor. The response rate of current FDA
approved therapies, azacitidine, decitabine and lenalidomide, is low and often not
durable. Just about 50% of MDS patients respond to these drug therapies and a
majority of responders relapse within 2-3 years27,29. A follow up study of 5q MDS
8

patients found that achieving erythroid and cytogenetic responses on
lenalidomide does not prevent progression to AML30.
The prognosis of patients who do not respond to azacitidine or decitabine
is even more abysmal with an overall survival of < 6 months31. Several
cytogenetic abnormalities are observed in MDS but deletions or complete loss of
chromosomes 5 and/ or 7 are the most commonly observed11,16. The prognosis
of patients with complete loss of chromosomes 5 and/ or 7 is significantly
unfavorable compared to other karyotypes11. It has been recognized for a long
time that hematopoietic stem cell transplant (HSCT) is the only available
potentially curative treatment for MDS but the use of HSCT for MDS remains low
to date, < 10% of MDS patients are referred for HSCT 20,31,32,. A study of 27 tMDS cases found that all treatments but HSCT, were not effective for MDS
resulting in 100% fatality in patients < 55 years17. Although potentially curative,
HSCT treatment for MDS can fail in certain instances33,34. Several factors, such
as age and intensive preconditioning regimens could adversely impact the
success of HSCT for MDS treatment33. One study assessed the impact of age on
the outcome of HSCT in cancer patients in general. They found a 2.24 fold
increased risk of treatment related mortality in patients aged ≥ 50 years35. This is
particularly true for the older patients in whom age and comorbidities limit
tolerability to intensive preconditioning HSCT treatments31. Given that current
MDS treatments are mostly ineffective and the high risk of disease-related
complications especially from anemia, there is an unquestionable need to
investigate potential alternative therapeutic options for MDS.
9

WITHAFERIN A (WFA)
Although great advancements have been made in the treatment of cancer,
toxicity is a major problem with most of the established chemotherapy drugs
routinely used for cancer treatment36. It is strongly believed that the use of plant
derived compounds for cancer treatment could reduce adverse side effects
because they are natural36-38. Withaferin A (WFA) is a plant-derived compound
that has been shown to have potential in anticancer treatment39. It is one of the
most bioactive steroidal lactones (Figure 1.2) isolated from the winter cherry
plant, Withania somnifera40. Withania somnifera, also known as “Indian Ginseng”
or “Indian Winter cherry” has been used in herbal formulations for centuries in
Ayurvedic medicine for a wide range of ailments such as chronic fatigue,
dehydration and rheumatism41,42. Ayurvedic medicine is a traditional healthcare
system which originated from India more than 3, 000 years ago that uses a
variety of herbal compounds, special diets, exercise and lifestyle
recommendations43. WFA exhibits anticancer effects by targeting several
processes known to promote cancer. Studies have demonstrated that WFA can
inhibit cell proliferation, angiogenesis, metastasis, inflammation, and induce
apoptosis in cancer model systems41,44. The therapeutic potential of WFA in
cancer is illustrated by the fact that it has been shown to have anticancer effects
in several cancers including prostate, breast, cervical and pancreatic cancers, as
well as melanoma and lymphoma44,45. Although anticancer activities of WFA
have been studied in several systems, the molecular mechanisms underlying
these activities are not completely understood. In silico analysis identified
10

vimentin, IKKγ and Cdc37 as possible direct molecular targets of WFA41. Direct
interactions of vimentin and IKKβ with WFA have been demonstrated46,47. There
is also strong evidence suggesting WFA directly binds to heat shock protein 90
(Hsp90), a molecular chaperone which mediates the folding, assembly and
maturation of client proteins such as the pro-survival protein AKT48. WFA
regulates the activity of several transcription factors and kinases but it is not
known if this regulation is by direct or indirect mechanisms41,44. WFA has also
been shown to inhibit complex III activity in mitochondria but it was not
investigated if a direct interaction occurred between the two molecules49. It is
now clear that WFA can target multiple pathways and the pathways targeted
could be cell type specific44,50. Therefore, the critical pathway for each system
would need to be determined systematically. Some commonly reported
mechanisms by which WFA inhibits proliferation and/ or induces apoptosis of
cancer cells include induction of cell cycle arrest 45,51-57, inhibition of NF-κB 45,58, and increased production of reactive oxygen species (ROS)49,62-66.

63
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REACTIVE OXYGEN SPECIES (ROS)
ROS are a heterogeneous group of oxygen-containing species with highly
reactive chemical properties67,68. ROS exist in two flavors; radicals which contain
one or more unpaired electron(s), and non-radical species which are equally
reactive but lack unpaired electron (s) and can be converted to radical species68.
Examples of radical and non-radical ROS commonly seen in biological systems
are listed in Table 1.569. There are both exogenous and endogenous sources of
ROS. Some exogenous sources of ROS include γ-irradiation, UV irradiation,
ultrasound, food, drugs, pollutants (e.g. car exhaust, cigarette smoke and
industrial contaminants), xenobiotics, and toxins69. There are multiple
mechanisms by which cells produce ROS endogenously. Electron leakage from
the mitochondrial respiratory chain is a major source of endogenous ROS
12

production68,70. ROS can also be produced as a by-product of certain enzymatic
reactions such as, catabolism of purines, fatty acid peroxidation, prostaglandin
synthesis and detoxification reactions by cytochrome P45068,70. Some enzymes
are direct producers of ROS such as nitric oxide synthase which produces nitric
oxide (NO.)69. Phagocytic cells activated by recognition of an antigen undergo a
series of reactions called the respiratory burst that is catalyzed by nicotinamide
adenine dinucleotide phosphate-oxidase (NADPH-oxidase), which is another
source of endogenous ROS production71.

13

EFFECTS OF ROS
Given that ROS are chemically reactive, they can react with cellular
components such as lipids, proteins, carbohydrates and nucleic acids to cause
tissue damage69,70. The antioxidant defense system has evolved to counteract
the damaging effects of ROS in body tissues72. Antioxidants act by direct and
14

indirect mechanisms to terminate oxidative chain reactions by deactivating
already formed ROS and by preventing ROS generation73. The antioxidant
defense system consists of both enzymatic and non-enzymatic molecules72.
Enzymatic antioxidants include superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx)70,72. Ascorbic acid (Vitamin C), α-tocopherol
(Vitamin E), carotenoids, flavonoids, uric acid, coenzyme Q, lipoic acid, and
glutathione (GSH) are some non-enzymatic antioxidants known to play key roles
in antioxidant defense mechanisms70,72. GSH, a tripeptide of glutamine, cysteine
and glycine, is ubiquitously expressed in all mammalian tissues and is thought to
be the principal non-enzymatic antioxidant involved in antioxidant cellular
defense74. The importance of glutathione in redox metabolism is owed to its
ability to perform multiple roles including: GSH directly scavenges free radicals
and acts as a substrate for GPx during the detoxification of hydrogen peroxide
and lipid peroxides; GSH is a co-factor of several enzymatic antioxidants; GSH is
able to regenerate the active forms of non-enzymatic antioxidants, Vitamins C
and E70,75. Reduced glutathione (GSH) is converted to glutathione disulfide
(GSSG-oxidized glutathione) in oxidative stress74. Since glutathione is the major
redox buffer of the cell, the relative amount of the reduced and oxidized forms
(GSH/GSSG) is a good measure of oxidative stress or the redox state of an
organism74,76.
Paradoxically, physiological redox homeostasis favors mild oxidative
stress because ROS have some useful roles77. This means that the antioxidant
defense must minimize ROS damage while allowing the useful effects of
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ROS72,78. ROS have a critical role in the immune response against pathogens;
directly causing oxidative damage to phagocytosed pathogens or indirectly by
activating a variety of innate and adaptive mechanisms for pathogen
elimination79. Studies have shown that ROS are also important anti-inflammatory
and immunoregulatory molecules80. ROS can regulate signal transduction
pathways by activating kinases81 and transcription factors68,82, and by modulation
of intracellular calcium levels83. Redox signaling is integrated into a variety of
cellular processes such as: DNA damage response; antioxidant and antiinflammatory responses; regulation of iron homeostasis; cell differentiation,
metabolism and migration; cell proliferation; and apoptosis68,81,84.
ROS AND CELL CYCLE PROGRESSION
There is overwhelming evidence suggesting that cell cycle progression
and therefore cell proliferation is subject to redox control85,86. It is now
appreciated that the effect of ROS on cell cycle progression is influenced by
multiple factors. The type, amount and location of ROS production, duration of
ROS exposure, and the presence or absence of other proteins like cell division
cycle 25 (Cdc25), are examples of factors that affect redox signaling on cell
cycle85,87. Cyclin dependent kinases (Cdks), cyclins and Cdk inhibitors cooperate
to ensure a precise and orderly progression through the cell cycle88. Hence, ROS
impacts cell cycle progression by regulating the activity and expression of these
cell cycle regulators via phosphorylation, ubiquitination and other protein
modification events85,87,89. ROS mediated regulation of cell cycle progression is
very complex but induction of the Cdk inhibitor p21, seems to have a crucial
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role85. Increased p21 expression causes cell cycle arrest90. ROS can induce p53independent expression of p21 through redox sensitive transcription factors like
activator protein-1 (AP-1) and specificity protein 1 (Sp1)85. Alternatively, ROSinduced DNA damage can lead to increased p53 activity which in turn induces
p21 expression85,90. Expression of p21 plays a unique role in redox-regulated cell
proliferation because temporal expression allows for DNA damage repair by cell
cycle arrest and resumption of proliferation once redox homeostasis is achieved
and p21 levels are normalized. However, prolonged ROS production sustains
p21 expression and cells eventually undergo apoptosis85. In fact, p21 has been
shown to be involved in the transcriptional repression of several cell cycle genes
including cyclins and Cdks91.
ROS AND JNK-MEDIATED APOPTOTIC SIGNALAING
c-Jun N-terminal Kinases (JNKs) are a subfamily of the mitogen-activated
protein kinase (MAPK) superfamily comprised of three well-characterized
members: extracellular signal-regulated kinases (ERKs), p38 MAPKs, and
JNKs92. MAPKs regulate cellular responses to external stimuli and cellular
processes including cell proliferation, differentiation, and apoptosis92,93. MAPKs
mediate most of the signal transduction in eukaryotic cells by modulating the
activity, degradation, subcellular localization, and protein interactions of their
target proteins via phosphorylation94. MAPKs are activated via a three-tier
signaling cascade module in which a MAPK kinase kinase (MAP3K) activates a
MAPK kinase (MAP2K) that in turn activates a MAPK92. JNKs are at the last tier
of this signaling module.
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JNKs are encoded by three distinct genes, two of which are ubiquitously
expressed (JNK1 and JNK2) and JNK3, whose expression is restricted to the
heart, brain and testes95,96. All three genes are alternatively spliced into ten
variants from which both 46kDa and 54kDa isoforms are derived96. MKK4 and
MKK7 are two MAP2Ks known to directly phosphorylate JNKs93,95,97. Unlike
MKK4 which can activate JNK and p38 MAPK, MKK7 is highly specific to JNK
activation98. At least twelve MAP3Ks have been observed to be involved in MKK4
and MKK7 activation, including the ROS sensitive MAP3K, apoptosis signalregulating kinase 1 (ASK1)81,99.The first target of active JNKs identified was cJun, hence their naming100. c-Jun is a subunit of the AP-1 family of transcription
factors that consists of homodimers and heterodimers of Jun (c-Jun, JunB,
JunD), Fos (c-Fos, FosB, Fra-1, Fra-2) or activating transcription factor 2 (ATF2)
proteins101. Active JNKs activate c-Jun by phosphorylating serines 63 and/or 73
in the amino terminal A1 transactivation domain102,103. It is now recognized that
JNKs can modulate the activity of a myriad of proteins ( both nuclear proteins,
most of which are transcription factors, and non-nuclear proteins) positively or
negatively by phosphorylation100. c-Jun, ATF2, Elk-1, c-Myc, p53, FOXO4,
STAT3 and PAX2 are examples of nuclear proteins positively regulated by JNKs
while HSF1, PPARγ1, Nur77, TIF1A, NFATc3 and Androgen R are some of the
nuclear proteins inhibited by JNKs100. Some non-nuclear proteins activated by
JNKs are Bim, Bax, MK1, Bcl-2 and Itch, while Bcl-XL, IRS-1, Bcl2, Tau and
kinesin - are examples of non-nuclear proteins that have been shown to be
inhibited by JNKs100. Several cellular responses; morphogenesis, metabolism,
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motility, DNA repair cell differentiation, cell proliferation, cell survival, and cell
death, are controlled by these JNK substrates104,105. Hence not surprisingly,
JNKs are implicated in a number of diseases including cancer104,105. Since the
cellular response to JNK activation is cell type and context dependent93,106, it can
either promote or inhibit disease states105,107.
It is well known that ROS-induced activation of JNKs via the redox
sensitive MAP3K, ASK1, leads to cellular apoptosis93,108. The thioredoxin
(Trx)/ASK1 complex functions as the redox switch of ROS-induced ASK1/JNK
apoptosis signaling108. Homophilic interaction of ASK1 mediated by the Nterminal coiled coil (NCC) domain is required for activation of the ASK1109. The
reduced form of Trx but never the oxidized form is found in complex with
ASK1110. Binding of Trx to the N-terminal Trx-binding region of ASK1 inhibits its
NCC domain-mediated homophilic interactions and therefore its activation109,110.
Increase in ROS levels results in oxidation of Trx which dissociates from the
Trx/ASK1 complex, enabling ASK1 activation109,110 (Figure 1.3). Active ASK1
phosphorylates and activates JNKs which regulate apoptosis by nuclear and
mitochondrial signaling events93. Activated nuclear JNK promotes AP-1 mediated
expression of pro-apoptotic proteins like BIM111,112 and Fas-ligand (Fas-L)113.
Active JNK on the other hand can translocate to mitochondria where it directly
activates the mitochondrial apoptosis machinery in the absence of new protein
synthesis114. Phosphorylation of mitochondrial proteins such as Bcl2 and Bcl-xL
and decreased mitochondrial membrane permeability by active JNK have been
reported to induce mitochondrial apoptosis114,115.
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ROS IN CANCER
Evidence suggests the malignant cells in most cancers including MDS,
have increased levels of ROS compared to their normal counterparts116-119. A
delicate balance of ROS levels is essential for normal cell growth and survival
since a moderate increase ROS can promote cell proliferation while excessively
high concentrations of ROS lead to cell death85. Since cancer cells are already in
a state of increased oxidative stress, they could be more susceptible to agents
that further increase ROS generation67,116. Hence, manipulation of ROS levels
could be a means to selectively target cancer cells while sparing normal cells
68,116

. Indeed there have been several reports demonstrating the selective

therapeutic potential of some agents by increased ROS production119-123.
Modulation of ROS homeostasis has been extensively exploited for AML therapy
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in the past decade124 but this therapeutic strategy has not been exploited for the
closely related disease, MDS. The implication of increased oxidative stress in the
development and prognosis of MDS118 suggests ROS producing agents such as
WFA could have therapeutic value in MDS.
STUDY MODEL AND OBJECTIVES
There is no widely accepted animal model that completely recapitulates
clinical features of MDS. Engraftment of primary MDS cells into
immunocompromised mice is poor and highly inefficient125,126. We therefore used
the human MDS-L cell line, a subline of MDS92127 for this study. The MDS92 cell
line was derived from the bone marrow of an MDS patient128 and was described
by an independent group of investigators as the “chosen one” of the 31 cell lines
investigated129. MDS-L cells have deletions in chromosomes 5 and 7127, the most
common cytogenetic abnormalities observed in MDS which have also been
associated with significantly worse prognosis12,14,16,17. Moreover, MDS-L cells
successfully engraft and induce reproducible disease in NOD/SCID-IL2Rᵧ (NSG)
and NSG-hSCF/hGM-CSF/hIL3 (NSGS) mice130.
As discussed above, the prognosis of MDS patients is generally very poor
but the treatment options for these patients are very limited. The anticancer
potential of the plant derived-compound, WFA has been demonstrated in several
cancer models including prostate, breast, cervical and pancreatic cancers, as
well as melanoma and lymphoma44,45. In this study, we utilized the MDS-L model
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of MDS to investigate the anticancer potential of WFA in MDS by addressing the
following specific aims:
1. Determine the in vitro and in vivo effects of WFA on MDS-L cells and primary
bone marrow cells from MDS and AML patients.
2. Elucidate the mechanisms of action of WFA in this MDS model.

Copyright © Karine Zinkeng Oben 2017
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CHAPTER 2
MATERIALS & METHODS
2a) Cell Culture
MDS-L cells (a generous gift from Dr. Kaoru Tohyama, Department of
Laboratory Medicine, Kawasaki Medical School, Japan) were maintained in
IMDM/F-12 (50:50) medium supplemented with 12% fetal bovine serum (Atlanta
Biologicals), 0.005mg/ml apotransferrin, 50 µM 2-mercaptoethanol (2-ME) and 20
ng/ml of human IL-3 (PeproTech). KG-1 cells (kindly provided by Dr. Ying Liang,
Department of Toxicology and Cancer Biology, University of Kentucky, USA)
were cultured in IMDM medium supplemented with 10% fetal bovine serum. KG1
is a human AML cell line. IRB protocol # 88-00241 permitted acquisition of
human primary cells. Normal human primary bone marrow cells were courtesy of
Dr. Ahmed Abdel-Latif at the University of Kentucky. Bone marrow mononuclear
cells were isolated by Ficoll-paqueTM plus (GE Healthcare) and maintained in
RPMI medium supplemented with 50 µM 2-mercaptoethanol, 1 µM sodium
pyruvate and 10% fetal bovine serum (FBS). MDS/AML samples were obtained
from Leukemia Tissue Bank of the Ohio State University Comprehensive Cancer
Center (OSU CCC). MDS/AML cells were thawed and maintained in RPMI
medium supplemented with 10% fetal bovine serum and 10 ng/ml hIL-3, GMCSF and stem cell factor (R&D Systems). All media were purchased from GibcoLife Techonologies.
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2b) Reagents
WFA was isolated from Withania somnifera extract (Sabinsa Corp) using a
series of solvent extractions and silica gel-based vacuum liquid column
chromatography at the University of Louisville and at the laboratory of Dr. I. P.
Singh, National Institute of Pharmaceutical Education Research (NIPER), India.
The purity was found to be >94% by UPLC. WFA was reconstituted in dimethyl
sulfoxide (DMSO). Biotin conjugated rat anti-CD45R/B220 (553086), anti-CD11b
(553309), anti-Gr-1 (553125), anti-CD8a (5532029), anti-Ter-119 (553672), antiCD5 (553019); streptavidin APC CY7 (554063) and anti c-KIT-APC (553356)
were purchased from BD Pharmingen (San Diego, CA). Anti-Sca-1-PB (122520)
was purchased from BioLegend (San Diego, CA). Cremophor (C5135), Carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (C2920), hydrogen
peroxide (H2O2) (H1009), Phorbol 12-myristate 13-acetate (PMA) (P1585), Nacetyl-cysteine (NAC) (A8199), SP600125 (S5567), JNK-IN-8 (SML-1246), JC-1
(T4069), RNase A (R6513), Hepes solution (H0887), ethylenediaminetetraacetic
acid (EDTA) solution (E7889), dimethyl sulfoxide (D2438) and monoclonal anti-βactin (A5441) were purchased from MilliporeSigma-Aldrich (St. Louis, MO).
Antibodies to P-p38 (9211S), total p38 (9212), cleaved caspase-3 (9661S), total
caspase-3 (9665S), P-MKK7 (4171S), P-c-Jun (9261S), total c-Jun (9162), CDK2
(2546P), cyclin A (4656P), CDK1 (9116), cyclin B (4135) and GAPDH (2118S)
were obtained from Cell Signaling Technology (Danvers, Massachusetts). Antitotal MKK7 was purchased from Zymed (32-7000). Antibodies to RGS2
(100761), Hdac1 (7872), P-JNK (6254) and total JNK (571) were obtained from
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Santa Cruz Biotechnology (Santa Cruz, CA). Peroxidase coupled goat anti-rabbit
(SC-2004) and anti-mouse (SC-2005) Ig secondary antibodies were also
acquired from Santa Cruz Biotechnology (Santa Cruz, CA). 1X phosphate
buffered saline (16750-078) was obtained from VWR (Radnor, PA).
2c) MTT and Trypan Blue Dye Exclusion Cell Viability Assays
MDS-L cells were treated with increasing concentrations of WFA (0 – 20
µM) in 96 well flat-bottom microtiter plates for 48 h in 0.2 ml of media. Cells were
cultured in quadruplicates. Treated cells were incubated with 0.5 mg/ml MTT (3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye (Sigma Aldrich)
for 4 h followed by solubilization of formazan salt with acidic isopropanol and
spectrophotometric measurements at 560 nm and 690 nm. Optical density
variation was corrected by subtracting OD 690 from OD 560 nm values. Media
background was subtracted from all treatment groups and a DMSO control group
was included in each experiment. For trypan blue exclusion, MDS-L cells were
treated with increasing concentrations of WFA (0 – 20 µM) in 0.5 ml of media per
well of 24 well flat-bottom plates for 48 h and cell viability was assessed by
counting live cells by trypan blue exlusion.
2d) Effect of WFA on MDS-L Engraftment in vivo
Animal studies were conducted under an approved protocol by the
Institutional Animal Care and Use Committee (IACUC) at the University of
Kentucky (Protocol # 2011-0904). NOD/SCID-IL2Rᵧ-hSCF/hGM-CSF/hIL3
(NSGS) breeding pairs were obtained from The Jackson Laboratories (Bar
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Harbor, ME) and bred at the University of Kentucky’s Division of Laboratory
Animal Resources (DLAR) AAALAC certified animal facility. Animals had free
access to food and water, and were housed at constant temperature with a 12
hour light–dark cycle. 6 -7 month old male and female littermates were exposed
to 2.5Gy irradiation (IR) in a Mark I-68 137Cesium γ-irradiator (J.L Shepherd and
Associates) on a rotating platform, as a pre-conditioning regimen for bone
marrow engraftment. Four hours after irradiation, mice were engrafted by
intravenous tail vein injection with MDS-L cells (1 Х 106 cells in 100 µl/mouse).
Mice were treated from day 14 with 8 mg/kg of WFA IP 5X a week for 6
weeks. Control mice received vehicle (10% DMSO, 20% Cremophor-Ethanol
(1:3), 70% phosphate buffered saline (PBS)). MDS-L engraftment was assessed
by the percentage of human CD45+/CD33+ double positive cells in the bone
marrow compartment since MDS-L cells are positive for these markers. Tibiae
and femora were harvested from mice and the bones were flushed with a 26G
syringe in HBSS containing 2% fetal bovine serum to obtain bone marrow cells.
The cells were washed and suspended in fluorescence activated cell sorter
(FACS) buffer (1X phosphate buffered saline without calcium or magnesium,
supplemented with 25mM Hepes, 5mM EDTA and 1% FBS). 2 × 106 cells were
stained with anti-mouse CD45-APC, anti-human CD45-PE and anti-human
CD33-PE for 1 h at 4°C in the dark. Positively stained cells were detected by the
BD LSRII flow cytometer and the data was analyzed by the FlowJo (Ashland,
OR) single cell analysis software. Anti-human CD45-PE (12-9459-42) and CD33-
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FITC (11-0339-42) were purchased from eBioscience (San Diego, CA). Antimouse CD45-APC was obtained from BioLegend (San Diego, CA).
2e) Staining and identification of bone marrow stem cells
Bone marrow cells were incubated with normal rat IgG (10 µg/1 × 106
cells) at 4 °C for 15 min to block Fcγ receptors and then labeled with biotin
coupled rat anti-mouse lineage specific antibodies to CD11b (Mac-1), B220, Gr1, CD8α, Ter-119 and CD5. The cells were stained with c-KIT-APC, Sca-1-PB
and streptavidin APC CY7 antibodies for 30 min at 4°C in the dark and washed
with 1X FACS buffer. Positively stained cells were detected on the BD LSRII flow
cytometer and data was analyzed by the BD CellQuest™ Pro software. Lineage
negative cells which were double positive for both Sca-1 (stem cell antigen-1)
and c-KIT (LSK) were identified as stem cells.
2f) Annexin-V Apoptosis Assay
The annexin-V apoptosis detection kit (A432) from Leinco Technologies
(St. Louis, MO) was used for annexin-V assays. Thawed human primary
MDS/AML cells were maintained in culture for 24 h and then treated with
increasing concentration of WFA for 24 h. Treated cells were stained with
annexin-V-FITC and PI following the manufacturer’s protocol. Data was acquired
with the Becton-Dickinson FACSCalibur flow cytometer and analyzed by the BD
CellQuest™ Pro software (San Jose, CA). For MDS-L cells, 7.5 X 105 cells/ml
were treated with increasing WFA concentrations for 48 h before staining. In the
case of JNK or ROS inhibition studies, 7.5 X 105 MDS-L cells/ml after a 4 h JNK27

IN-8 (10 µM) or NAC (25 mM) pretreatment, or no pretreatment were treated with
WFA (10 µM) for 24 h and stained with annexin-V/PI. Stained MDS-L cells were
detected by the BD LSRII flow cytometer and BD CellQuest™ Pro software was
used for data analyses.
2g) NF-κB Nuclear Translocation by Immunocytofluorescence
MDS-L cells (5 X 106) were incubated with WFA (10 µM) or DMSO for 4 h.
The cells were fixed with 70% ethanol for 1 h, blocked for 1 h in 10% normal goat
serum and stained with 1:200 dilution of NF-κB p65 primary antibody (Santa
Cruz-372) overnight at 4 0C. Cells were washed and stained with 1:200 DyLight
488 conjugated AffiniPure F(ab')2 goat anti-rabbit secondary antibody (Jackson
Immunoresearch #111–486–046) for 1 h in the dark. After 1X wash with FACS
buffer, the cells were again stained 1:4000 DAPI (Life Technologies, #D1306) for
15 min at room temperature. ProlongR Gold Anti-Fade Reagent (Life
Technologies, #P36930) was used to mount the cells after washing following
DAPI staining. Slides were viewed and pictures taken on a FV1000 v1.5 confocal
microscope (Olympus, Shinjuku, Tokyo, Japan).
2h) Immunoblotting
MDS-L cells (7.5 X 105 cells/ml) were cultured with 10 µM WFA or DMSO
for different time points. Cells were lysed in Cell Signaling lysis buffer (#9803)
containing 1mM PMSF (Sigma P7626), 2mM NaF (Sigma S-1504), 2mM
Na3VO4 (Sigma S-6508) and 1x protease inhibitor cocktail (Roche 5892953001).
To obtain nuclear and cytoplasmic lysates, the cell pellets were lysed following
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the Thermo Scientific Nuclear and Cytoplasmic Extraction kit (#78833) manual.
Protein concentration in cell lysates was estimated by the Bicinchoninic Acid
(BCA) assay kit (Thermo Scientific #23227). Protein lysates were diluted in 4x
sodium dodecyl sulfate (SDS) sample buffer (100mM Tris-HCl, pH 6.8, 30%
glycerol, 4% SDS, 5% 2-ME and 0.01% W/V bromophenol blue) to a 1x final
concentration and boiled for 10 min. 35 µg total protein/sample of total lysate was
subjected to SDS polyacrylamide gel electrophoresis. 10 µl of Precision Plus
ProteinTM dual color ladder (BIO-RAD #1610394) with a size range spanning10250 kDa was used as a size standard for every gel. The BIO-RAD Mini
PROTEAN Tetra System was used for both gel electrophoresis and transfer. 12,
10 or 9% polyacrylamide gels were run with running buffer (25 mM Tris, 192 mM
glycine, 0.1% SDS, pH 8.3) at 90 V and 3 A for 10 min to stack the proteins, and
later at 140 V and 3 A for 1 h to separate the proteins. Separated proteins were
transferred to polyvinylidene difluoride membranes (EMD Millipore IPVH00010)
with transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3).
Transfer was performed at 90 V and 300 mA for 1.5 h at 40C. Membranes were
blocked at room temperature for 1 h with 5% milk or bovine serum albumin (when
probing for phosphorylated proteins) in 1x TBST that was diluted from 10x TBST
(0.5 M Tris, 1.5 M NaCl and 1% Tween-20). The membranes were then probed
with appropriate primary antibodies at 40C overnight, followed by horseradish
peroxidase-conjugated secondary antibodies at room temperature for 1 h.
Membranes were washed 7X with 1x TBST after primary or secondary antibody
incubations. The blots were developed with HyGLO chemiluminescence reagent
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(Denville Scientific #E2400) and exposed to HyBlot CL autoradiography film
(Denville Scientific #E3012), which were scanned with a flat-bed scanner (UMAX
Technologies, Hsinchu, Taiwan). When comparing two blots, both gels were run
side by side and the blots were developed on the same film. Band densitometry
analysis was performed using the NIH ImageJ program. Protein expression was
normalized to GAPDH, β-actin or total target protein expression as appropriate.
2i) Affymetrix Microarray Analysis
Gene expression profile of MDS-L cells was examined in triplicate
samples. 10 X 106 MDS-L cells were treated with WFA (10 µM) or DMSO for 6 h
or 12 h at 370C in a CO2 incubator. Total RNA was extracted using the DirectzolTM RNA miniprep kit (Zymo Research #R2051) according to the
manufacturer’s instructions. The Agilent RNA 6000 Nano assay kit (#5067-1511)
was used to assess RNA purity on the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). RNA integrity number (RIN) was ≥ 9 for all
samples. WT Plus Reagent kit (Affymetrix, Santa Clara,CA), was used to
generate amplified and biotinylated sense-strand DNA (ss-cDNA) from 100 ng
total RNA per sample. 30 µg of fragmented biotin-labelled ss-cDNA was
hybridized to Affymetrix human gene 2.0 ST arrays at 45 0C and 60 rpm for 16 h.
The arrays were washed and stained using Affymetrix fluidics station FS 450 and
scanned using the Affymetrix 7G GeneChip Scanner. Data was collected using
the Affymetrix Command Software. The raw microarray data files were
processed through Oligo [Doi:10.1093/bioinformatics/btq431] for data extraction
and normalization. Differential expression analyses comparing WFA-treated
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groups and the control group were performed by limma
[DOI:10.1093/nar/gkv007]. Significantly up/downregulated genes were
determined as fold change > 3 and q-value < 0.05, where q-value is a p-value
corrected for multiple testing. The functional analyses were performed through
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity). The heat map was used to demonstrate the
expression of differentially expressed genes, where genes belonging to the top
15 enriched diseases and function categories from IPA were highlighted. The
gene set enrichment analysis was performed using GSEA software and the
Hallmark gene sets in the Molecular Signature Database (MSigDB)131
[http://www.broad.mit.edu/gsea/].
2j) Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from BM-MNCs using TRIzolR reagent
(LifeTechnologies #15596-018) according to the manufacturer’s instructions.
cDNA was synthesized from 500 ng of total RNA with qScript reverse
transcriptase (Quanta Biosciences #95048-100) using random and oligo(dT)
primers as per manufacturer’s protocol. The CFX96™ Real-Time C1000 Touch
thermal cycler system (BIO-RAD, Hercules, California) was used with the iTaqTM
universal SYBRR green fluorescent supermix (Biorad #172-5121) to quantify
mRNA expression. RNA polymerase II was used as an internal control. BIO-RAD
CFX Manager software was used to perform relative quantification of target
genes using the comparative CT (ΔΔCT) method. Specificity of PCR reactions
was confirmed by melting curves. The primer sequences used are described in
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Table 2.1. Primers were designed on NCBI/Primer-Blast using the default
parameters with the following modifications; primer must span exon-exon
junction, primer must have at least 6 total mismatches to unintended targets and
ignore targets that have one or more mismatches to the primer. Primers were
obtained from Integrated DNA Technologies (IDT, Coralville, Iowa).
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2k) Mitochondrial Membrane Potential by JC-1
MDS-L cells (7.5 X 105 cells/ml) were exposed to WFA (10 µM) or DMSO
for 8 h. Cells treated with 50 µM of the proton translocator, FCCP for 2 h were
used as a positive control. JC-1 was added at a 1 µM final concentration to cells
for the last 30 min of treatment at 37 0C. The cells were washed, suspended in
PBS and fluorescence was measured using the iCyt Synergy sorter system
(Sony Biotechnology Inc., San Jose, CA). We used the 488 and 561 nm lasers
because the 561 nm laser efficiently excites J-aggregates but does not excite JC1 monomers132. This ensured optimal discrimination of the JC-1 monomers from
the aggregates. The WinList 3d 8.0 software (Verity Software House Inc.,
Topsham, Maine) was used for data analyses.
2l) ROS Measurement
Cell permeant 6-Carboxy-2',7'-Dichlorodihydrofluorescein Diacetate
(Carboxy-H2DCFDA) (ThermoFisher Scientific #C400), was used as an indicator
for intracellular ROS measurement. MDS-L cells were treated with DMSO, WFA
(10 µM) or H2O2 (1mM) for 30 min at 37 0C. Alternatively, cells were treated with
N-acetyl-cysteine (NAC) (25 or 50 mM) for 4 h followed by DMSO, WFA (10 µM)
or H2O2 (1mM) for additional 30 min at 37 0C. Treated cells were washed with
warm 1X PBS and suspended in warm H2DCFDA solution (1.25 µg/ml in PBS).
The cells were incubated in the dark at 37 0C for 20 min. Fluorescence was
detected on the BD LSR II flow cytometer and the BD CellQuest™ Pro software
was used for data analyses. The oxidized form of DCFDA, 5-(and-6)-Carboxy-
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2',7'-Dichlorofluorescein Diacetate (Carboxy-DCFDA (ThermoFisher Scientific
#C369), was used as a control for uptake, cellular esterase activity and decay.
2m) AP-1 Luciferase Assay
AP-1 pGL3 promoter luciferase and empty vectors were kindly provided by
Dr. Sanjit Dhar, Department of Toxicology and Cancer Biology, University of
Kentucky, USA. The Tk-renilla luciferase vector was a generous gift from the
laboratory of Dr. Martha Peterson, Department of Microbiology, Immunology and
Molecular Genetics, University of Kentucky, USA. MDS-L cells were transfected
by electroporation. 2.5 X 106 cells were co-transfected with 20 µg of Tk Renilla
luciferase vector and 40 µg of firefly luciferase vector (AP-1 or empty vector) at
250 mV, 960 µF and 200 Ω in 200 µl of MDS-L culture medium with a Gene
Pulser electroporator (BIO-RAD, Hercules, CA). Transfected cells were cultured
in MDS-L culture medium for 24 h at 8.5 X 105 cells per well in 6 well flat bottom
plates (Corning #353224). 24 h after transfection, 1 X 105 cells per well were
treated with 10 µM WFA or 30 ng/ml phorbol 12-myristate-13-acetate (PMA) for
12 h in white 96 well flat bottom polystyrene plates (Corning #3917, Corning
Incorporated Inc, Durham, NC). Alternatively, cells were pretreated with NAC
(25mM) for 4 h before WFA treatment for an additional 12 h. Promoter activity
was assessed by the Dual-Glo® Luciferase assay system (Promega #E2920,
Promega Corporation, Madison, WI). Luminescence was measured using the
GloMax® Explorer luminometer (Promega). Media background luminescence
was subtracted and the ratio of firefly to renilla luminescence was calculated.
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2n) Cell Cycle Analyses
MDS-L cells (7.5 X 105 cells/ml) were exposed to increasing concentration
of WFA (0 – 5 µM) for 48 h. Treated cells were fixed with cold 70% ethanol for 1
h at 4 0C. The cells were washed 3X with PBS and incubated in a Propidium
Iodide (PI) and RNase A cocktail (20 µg/ml and 250 µg/ml respectively, in 0.1%
Triton X-100 in PBS) at 37 0C for 30 min. PI fluorescence was detected on the
BD FACSCalibur flow cytometer and analyses were performed using the ModFit
Software (Verity Software House Inc., Topsham, Maine).
2o) Statistical Analysis
GraphPad Prism 6.05 was used for statistical analyses (GraphPad
Software, Inc., La Jolla, CA). Statistical significance of differences between
groups was evaluated by Student’s t test, linear regression analysis or Tukey’s
multiple comparisons test as appropriate and p values < 0.05 were considered
significant.
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CHAPTER 3
WFA has a potent but selective anti-proliferative effect on MDS-L cells in
vitro and in vivo
The complex and heterogeneous nature of MDS has made it challenging
to generate a widely accepted mouse model that recapitulates a complete
disease phenotype133. Efforts to develop a xenotransplantation model of primary
MDS cells into immunocompromised mice have been thwarted by poor and
highly inefficient bone marrow engraftment of these cells125,126. Development of
cell line models for MDS has not been met with much success either. Several
human MDS cell lines have been described in the literature but only the MDS-L
cell line has been validated to be a legitimate cell line that is representative of
MDS129. MDS-L is a subline of the MDS92 cell line that was derived from the
bone marrow of an MDS patient127,128. Importantly, MDS-L cells successfully
engraft the bone marrow of immunocompromised mice to induce an MDS-like
disease that recapitulates some key features of human MDS130. Like human
MDS, the MDS-like disease induced by MDS-L engraftment is clonal1,130. In
addition, mice develop anemia and thrombocytopenia as the disease progresses,
two commonly observed cytopenias in human MDS3,130. The MDS-L model is
therefore considered an appropriate model for preclinical MDS studies and was
our model of choice to investigate the therapeutic potential of WFA in MDS.
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3a) WFA effectively decreased viability of MDS-L cells in vitro
Initial studies were performed to determine the effect of WFA on MDS-L
cells in vitro. WFA caused a dose dependent decrease in cell viability of MDS-L
cells by MTT assay (Figure 3.1A). Observed IC50 varied depending on the
seeding cell density. 2 – 3 μM when 0.75 Х 105 cells were seeded per well, 3 – 5
μM for 1 Х 105 cells and 5 - 7μM for 1.5 Х 105 cells (Fig 3.1A). The decrease in
viability of MDS-L cells by WFA was also demonstrated by trypan blue exclusion
assay. Similar to the MTT assay, WFA caused a dose dependent decrease in
viability of MDS-L cells by trypan blue exclusion (Figure 3.1B). Lenalidomide
(LENA) is the US Food and Drug Administration (FDA) approved treatment of
MDS with a deletion in chromosome 5q (del (5q))134. Since MDS-L cells have a
deletion in chromosome 5127, we evaluated how WFA compared to LENA in
inducing growth inhibition of MDS-L cells. To our surprise, WFA was substantially
more effective than LENA in inhibiting the proliferation of MDS-L cells in vitro
(Figure 3.2A). This observation was not dependent on the seeding cell density as
similar results were obtained even with a lower seeding cell density (Figure
3.2B). The markedly low or more of a complete lack of cytotoxicity by LENA on
MDS-L cells (Figure 3.2A, B) led us to consider the possibility that our drug might
be inactive since published reports have shown the cytotoxic effects of LENA on
MDS-L cells127 and human primary MDS cells with a 5q chromosomal deletion135.
To address this possibility, we replicated a published experiment in which the
effect of LENA on the proliferation of MDS-L cells was assessed by adding 10
μM of drug every 24 h and counting the number of viable cells over time127. The
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marked difference we observed between WFA and LENA was not due to drug
inactivation because addition of LENA every 24 h to MDS-L cells inhibited their
proliferation (Figure 3.3A) and our results were very similar to the published
results (Figure 3.3B). This requirement of replenishing LENA every 24 h in order
to observe its cytotoxicity might be due to its reported half-life of about 8 h in
vitro136. However, a single dose of LENA inhibited the proliferation of human
multiple myeloma cell lines136 . After establishing that we had to replenish LENA
every 24 h to observe its cytotoxic effects on MDS-L cells, we investigated
whether the cytotoxic effects of WFA and LENA could be combinatorial.
Combining a single dose of WFA to everyday addition of LENA on MDS-L cells
was not superior to either drug alone (Figure 3.4). In fact, WFA was distinctly
superior to LENA in inhibiting the proliferation of MDS-L cells under these
conditions. Since transformation to AML occurs in approximately 30 – 40% of
MDS cases135, we also investigated if WFA is cytotoxic to the human AML KG1
cell line. WFA caused a dose dependent decrease in viability of KG1 cells
(Figure 3.5).
3b) WFA inhibited bone marrow engraftment of MDS-L cells in NSGS mice
In vivo efficacy was evaluated using the MDS-L NSGS xenograft model,
where mice exposed to 2.5Gy irradiation are injected with 1 x 106 MDS-L cells 4
h later130. We chose to use NSGS mice for these studies because although
MDS-L was reported to successfully engraft the bone marrow of both NSG and
NSGS mice, we found engraftment to be less efficient in NSG mice (< 1%).
Irradiation serves as a preconditioning regimen to enhance bone marrow
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engraftment. We had found from our previous studies that the combination of
radiation and WFA was toxic to BALB/c mice. It was therefore essential to
determine the best tolerated dosing schedule for the radiation and WFA
combination especially since scid mice are hypersensitive to radiation137. We
found that NSGS mice had not completely recovered from radiation-induced
weight loss even at 14 days post exposure to 2.5Gy irradiation (Figure 3.6).
However, WFA treatment from day 14 post irradiation did not adversely impact
complete recovery by day 21 (Figure 3.6). We therefore decided to begin WFA
treatment on day 14 post irradiation and engraftment as illustrated in Figure 3.7A.
A combination of mouse and human cell surface markers was used to positively
identify engrafted MDS-L cells (Figure 3.7B). 8 mg/kg WFA treatment
significantly reduced engraftment of MDS-L cells in the bone marrow of NSGS
mice (Figure 3.7C, D). The 8 mg/kg dose was well tolerated as minimal weight
loss was observed in WFA treated mice compared to vehicle controls (Figure
3.7E). Remarkably, WFA treatment did not cause any apparent bone marrow
suppression of endogenous mouse stem cells at the dose used (Figure 3.8). This
is of particular importance because nearly all chemotherapy drugs cause bone
marrow suppression which leads to treatment delays and significant dose
reductions138. In fact, it is estimated that about 56% of patients on chemotherapy
receive less than 85% of the minimum optimal dose for treatment138. We also
found that WFA treatment expanded the stem cell population of non-engrafted
mice over control mice (Figure 3.8, p = 0.07). However, additional studies with a
larger sample size are needed to confirm this observation. While the prospect of
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stem cell expansion by WFA has potential therapeutic benefits, serial
transplantation studies are required to determine the functionality of these
expanded stem cells.
3c) Cytotoxicity of WFA is selective to malignant cells
The clinical relevance of the results obtained with the MDS-L and KG1 cell
lines were validated by testing the effect of WFA on the viability of human
primary bone marrow cells from MDS and AML patients. WFA induced a dosedependent increase in apoptotic cell death of primary MDS and AML bone
marrow patient cells (Figure 3.8A, B). The cytotoxic effects of WFA are selective
to malignant cells because it had no significant impact on the viability of normal
human primary bone marrow cells even at the highest dose tested (Figure 3.9).
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Figure 3.1: WFA significantly decreased the viability of MDS-L cells in vitro
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(A) MDS-L cells were treated with WFA at different cell densities (0.75 Х 105, 1 Х
105 or 1.5 Х 105 cells per well in 200 µl of media of a 96 well plate) for 48 h and
cell viability was measured by MTT assay. Data are presented as mean ± SD of
triplicate cultures. Results are representative of more than 3 experiments. (B)
MDS-L cells (7.5 X 105 cells/ml) were treated with increasing concentrations of
WFA for 48 h and cell viability was determined by trypan blue dye exclusion.
Data are presented as mean ± SD of triplicate cultures and results from one of 2
similar experiments are shown.
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Figure 3.2: WFA is substantially more cytotoxic to MDS-L cells compared to
lenalidomide
MDS-L cells were treated with WFA or LENA at 1.5 Х 105 cells (A) or 0.75 Х 105
cells (B) per well of a 96 well plate), for 48 h and cell viability was measured by
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MTT assay. Data are presented as mean ± SD of triplicate cultures. Data are
representative of three independent experiments. * = p<0.05, ** = p<0.005.
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Figure 3.3: Drug replenishment every 24 h is required to observe
lenalidomide-induced cytotoxicity of MDS-L cells
(A) MDS-L cells were cultured in the presence of DMSO or lenalidomide (10 μM)
which were added daily. The number of viable cells was counted by trypan blue
exclusion on the indicated days. Data are presented as mean ± SD of triplicate
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cultures. (B) Published data of a similar experiment using MDS-L cells and the
same concentration of lenalidomide. Reproduced with permission from Nature
Publishing Group; license number 3991040149727.
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Figure 3.4: The combined cytotoxic effects of WFA and lenalidomide are
neither additive nor synergestic
MDS-L cells were cultured with DMSO, lenalidomide (10 μM), WFA (5 μM) or
WFA (5 μM) and lenalidomide (10 μM). WFA was added on day one of the
experiment while lenalidomide was added daily during the course of the
experiment. The number of viable cells was determined by trypan blue exclusion.
Data are presented as mean ± SD of triplicate cultures. Representative data of
two independent experiments are presented.
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Figure 3.5: WFA significantly decreased the viability of KG1 cells in vitro
KG1 cells were treated with DMSO or WFA at 1.5 Х 105 cells per well of a 96 well
plate for 48 h and cell viability was measured by MTT assay. Data are presented
as mean ± SD of triplicate cultures. Results are representative of two
experiments.
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Figure 3.6: Toxicity from combining radiation and WFA treatment is
prevented by delaying WFA treatment
Mice were weighed on day 0 to determine baseline weights and exposed to
2.5Gy total body irradiation. On day 14 post irradiation, irradiated mice were
treated with WFA (8 mg/kg) for 5 consecutive days. Weights were monitored
during and after WFA treatment. Littermate mice neither exposed to radiation nor
treated with WFA were used as controls.
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Figure 3.7: WFA significantly reduced engraftment of MDS-L cells in the
bone marrow of NSGS mice
(A) Schematic representation of the experiment conducted to test the in vivo
effect of WFA in the MDS-L NSGS mice xenograft model. (B) Flow cytometry
gating scheme used for positive and specific identification of engrafted human
MDS-L cells. Bone marrow cells were stained with mouse anti-mouse CD45APC, and anti-human antibodies (CD45-PE and CD33-FITC) to identify mouse
and MDS-L cells respectively. The human markers were applied to the mouse
CD45 negative gate to ensure accuracy and specificity as false positive cells
were not detected in non-engrafted mice. (C) Representative flow cytometry
profiles of vehicle or WFA treated mice using the gating scheme illustrated in (B).
(D) Engraftment of MDS-L cells was calculated as a percentage of total bone
marrow cells. Average engraftment of 20 mice in the vehicle control group and 27
mice in the WFA group ± SD is shown. (E) Average weight variation of mice
during the course of the study. * = p<0.05.
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Figure 3.8: WFA treatment does not cause mouse bone marrow
suppression
Bone marrow cells from MDS-L engrafted and non-engrafted mice treated with
WFA or vehicle; or control mice were labeled with biotin-coupled rat anti-mouse
lineage specific antibodies to CD11b (Mac-1), B220, Gr-1, CD8α, Ter-119 and
CD5. Lineage negative, Sca-1 positive and c-KIT positive (LSK) stem cells were
identified by flow cytometry analyses of lineage labelled cells stained with
streptavidin APC CY7, Sca-1-PB and c-KIT-APC. Mean % of LSK cells for a
minimum of 5 mice per group ± SD is shown. ** = p<0.005
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Figure 3.9: WFA induced apoptosis of human primary MDS and AML bone
marrow cells
Human primary MDS (A) or AML (B) samples were treated with various
concentrations of WFA and stained with annexin-V and PI after 24 h of culture.
Cell viability was assayed by flow cytometry and the percentage of live or nonapoptotic cells defined as annexin-V and PI negative are shown.
Experiment performed in collaboration with Rajeswaren Mani DVM, PhD.
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Figure 3.10: WFA had no significant effect on the viability of normal human
primary bone marrow cells
Normal human primary bone marrow cells were treated with DMSO or WFA at 1
Х 106 cells per well of a 96 well plate for 48 h and cell viability was measured by
MTT assay. Data are presented as mean ± SD of triplicate cultures.
Representative results of two independent experiments are shown.
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Summary
WFA induced a dose dependent decrease in viability of MDS-L cells in
vitro. The IC50 varied by cell density per well. Dose response variability with cell
density suggests that a minimum threshold of drug might be required to induce
WFA cytotoxicity in cells, i.e, insufficient drug is available to meet that threshold
in all cells when high cell density is used. WFA was markedly more effective than
lenalidomide, the current FDA approved drug for the treatment of 5q MDS, in
inhibiting the viability of MDS-L cells in vitro. Consistent with the in vitro data,
WFA significantly inhibited engraftment of MDS-L cells in NSGS mice without
bone marrow suppression which is an important dose-limiting side effect of most
chemotherapy drugs. WFA was also cytotoxic to human primary MDS cells but
had no significant effect on the viability of normal human primary bone marrow
cells. We also found WFA to be cytotoxic to the AML cell line KG1 as well as
several human primary AML cells. These data suggest that WFA could be a
novel therapeutic agent for the treatment of MDS/AML with minimal side effects.
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CHAPTER FOUR
Signaling pathways involved in WFA-induced apoptosis in MDS-L cells
To investigate possible mechanisms mediating WFA-induced growth
suppression of MDS-L cells, our initial efforts tested whether the mechanisms
widely reported to mediate growth inhibitory effects of WFA in other cancer
models were true for MDS as well. Inhibition of NF-κB is amongst the
mechanisms most commonly reported to mediate the anticancer effects of
WFA41,44. NF-κB has been implicated in hematologic and solid tumors139. The
oncogenic potential of NF-κB is demonstrated by its ability to stimulate cell
proliferation, inhibit apoptosis and promote metastasis140. In fact, NF-κB has
been suggested as a potential therapeutic target in MDS139. Therefore, we tested
if NF-κB was involved in the inhibition of MDS-L cell survival by WFA. To our
surprise, NF-κB was unaffected by WFA treatment in MDS-L cells as shown by
both immunofluorescence (4.1A, B) and immunoblotting (4.1C) analyses of the
nuclear and cytoplasmic distribution of the p65 subunit. In fact, we found that NFκB was not constitutively active in MDS-L cells.
These results prompted us to perform mechanistic studies from a different
angle. We used gene expression changes mediated by WFA to explore possible
mechanisms mediating the cytotoxic effects of WFA in MDS-L cells. To this end,
we performed microarray gene expression analysis using the Affymetrix human
gene 2.0 ST array platform. The gene expression profile of MDS-L cells treated
with 10 μM WFA for 6 h or 12 h was compared to control. Three independent
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samples were used per experimental group. We focused on early time points in
an effort to identify primary gene alterations caused by WFA.
4a) WFA significantly altered expression of genes linked to cell death and
survival, cell growth and proliferation, cell cycle regulation and cancer
Differentially expressed genes between control and WFA treatment
groups determined as fold change > 3 and q-value <0.05 were used as input for
Bio Functional Analysis by the ingenuity pathway analysis (IPA) software. The
top 15 enriched biological functions and /or diseases most in the data set are
shown in Figure 4.2. Consistent with the results in chapter one, cell death and
survival, cell growth and proliferation, cell cycle regulation and cancer were
amongst the top significantly regulated biological processes at both 6 h (Figure
4.2A) and 12 h (Figure 4.2B). The top 10 elevated and repressed genes were
arranged according to fold changes and we found that c-Jun (Jun) and FosB
were among the top 3 up-regulated genes at 6 h and the top 2 up-regulated
genes at 12 h (Figure 4.3). We also performed gene set enrichment analysis
(GSEA) using the GSEA software to identify significantly enriched pathways.
WFA resulted in a highly significant enrichment in expression of apoptosis related
genes at both 6 h (Figure 4.4A, false discovery rate (FDR) q-value = 0.0001;
family-wise error rate (FWER) p-value = 0.0001) and 12 h (Figure 4.4B, FDR qvalue = 0.0001; FWER = 0.008). These results suggest the possibility that WFA
inhibited MDS-L proliferation and viability (chapter one) by inducing apoptotic cell
death.
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4b) WFA induced apoptosis of MDS-L cells
Pathway enrichment analyses of the microarray data revealed WFA
treatment significantly affected expression of apoptosis related genes (Figure
4.4). Therefore, we performed apoptosis assays to determine if changes in the
expression of these genes had a functional consequence on MDS cells. A
decrease in mitochondrial membrane potential (MMP) is a well-known indicator
of apoptosis141. So we tested if WFA decreased the MMP of mitochondria in
MDS-L cells. MMP measurement was performed by the widely used JC-1 assay.
JC-1 is a lipophilic cationic dye with a unique property in that it reversibly
changes color from orange-red to green as MMP decreases132. This property is
due to the ability of JC-1 to form aggregates at high concentrations within the
mitochondrial interior, which revert to monomers in the cytosol where
concentration decreases132. The concentration of JC-1 within the mitochondria of
viable cells is driven by the negative potential gradient between the mitochondrial
interior and the cytosol132. The negative potential gradient between mitochondrial
interior and the cytosol is lost as MMP decreases, causing a release of the dye
into the cytosol where it is less concentrated132. Therefore, a decrease in the
aggregate/monomer ratio is indicative of a decrease in MMP. Treatment of MDSL cells with WFA resulted in a significant decrease in MMP (Figure 4.5A, B).
During apoptosis, a decline in MMP ultimately results in the activation of
caspases141,142. Caspases are a family of proteases that are crucial regulators of
the apoptotic process and caspase-3 is the most frequently activated of the
known human caspases142. Immunoblotting analysis revealed that WFA activated
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caspase-3 in MDS-L cells as early as 6 h after WFA treatment which persisted at
12 h of WFA exposure (Figure 4.6). As expected, there was a concomitant
decrease in total caspase-3 (Figure 4.6). To further establish the apoptosis
induction by WFA, we performed an annexin-V apoptosis assay by flow
cytometry on WFA-treated MDS-L cells. Consistent with the MMP and caspase-3
data, WFA caused a dose-dependent increase in apoptotic cells (Figure 4.7A, B).
4c) WFA activated JNK MAPK signaling in MDS-L cells
After having confirmed that growth suppression of MDS-L cells by WFA
involved cell death by apoptosis, we next investigated possible signaling pathway
(s) mediating apoptosis of MDS-L cells treated with WFA. Apoptosis pathways
linked top up-regulated genes (Figure 4.3) were examined. Our process involved
verifying the microarray data and scouring the literature for evidence suggesting
the gene in question is involved in apoptosis induction. Bcl2-associated
athanogene 3 (BAG3) and Regulator of G-protein signaling 2 (RGS2) highlighted
in blue (Figure 4.3), are examples of genes which fell short, though they were
highly up-regulated. Although we were able to verify induction of BAG3 by qRTPCR (Figure 4.8), evidence from the literature suggest it plays more of an antiapoptotic role143. It is likely that BAG3 up-regulation was a secondary feedback
effect from the induction of apoptosis rather than the mediator. This highlights the
challenge of identifying primary gene expression changes from global gene
expression data sets. For RGS2 on the other hand, although there is evidence
from the literature suggesting RGS2 mediates apoptosis144-146, the microarray
data could only be validated at the mRNA but not at the protein level (Figure 4.9).
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In addition, the p38 MAPK pathway that is thought to be involved in RGS2
mediated apoptosis144 is not activated by WFA in MDS-L cells (Figure 4.9B). The
dramatic reduction in p38 MAPK activation at early time points may have some
role in reduction of RGS2 but the decrease in these proteins suggests a prosurvival role for them in the context of MDS-L cells. However, this was not further
investigated as we focused on genes that have positive effects on expression or
activation of pro-apoptotic molecules.
c-Jun and FosB were also among the top 3 up-regulated genes at 6 h and
the top 2 up-regulated genes at 12 h by WFA in MDS-L cells (Figure 4.3). c-Jun
and FosB can heterodimerize to form an AP-1 transcription factor that is
activated by phosphorylation of the c-Jun subunit by JNK93,101. It has been
demonstrated that apoptosis can be regulated by JNK/AP-1 signaling93. Hence,
we investigated if WFA activated JNK/AP-1 signaling in MDS-L cells. Even
though JNK signaling can be triggered by cytokine receptor signaling, we chose
to investigate an ROS mediated JNK activation pathway considering that ROS
production has been shown to mediate WFA effects in other cancer systems44,93.
JNK cascade activation can be mediated by the ROS sensitive ASK1 which
activates MKK7, the MAP2K known to specifically activate JNK98,108. Taking all
these facts together, we hypothesized that ROS mediated JNK activation will
have a role in AP-1 expression in MDS-L cells treated with WFA as illustrated in
Figure 4.10. To test this hypothesis, we first verified WFA-induced expression of
c-Jun and FosB by qRT-PCR. As can be seen from figure 4.11, there was a
robust increase in c-Jun (Figure 4.11A) and FosB mRNA (Figure 4.11B). Next,
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we examined if WFA treatment caused any changes in ROS production in MDSL cells since increase in ROS is the initiating event of the proposed signaling
pathway activated by WFA (Figure 4.10). WFA increased ROS accumulation in
MDS-L cells compared to DMSO control as measured by increased fluorescence
of the ROS sensitive dye, carboxy-H2DCFDA (4.12A, C). Pretreatment for 4 h
with NAC, a ROS scavenger, before adding WFA led to complete inhibition of
WFA generated ROS (Figure 4.12B, C). As illustrated in Figure 4.10, an increase
in ROS can lead to ASK1 activation which is the MAP3K upstream of MKK7.
Hence, we verified if the observed increase in ROS production by WFA activated
ASK1 by examining the phosphorylation status of MKK7. Indeed, we found that
WFA increased MKK7 phosphorylation or activation (Figure 4.13A). Given that
MKK7 solely activates JNK98, WFA treatment also led to increased JNK
activation as expected (Figure 4.13B). Activated JNK is known to translocate to
the nucleus where it phosphorylates c-JUN (Figure 4.10). Therefore, it was no
surprise that c-Jun phosphorylation was increased by WFA treatment (Figure
4.13C). The fact that c-Jun phosphorylation was only detectable at 6 h compared
to JNK phosphorylation which could be detected as early as 30 min, suggested a
sequential activation of the signaling cascade (Figures 4.10 and 4.13). Total cJun protein levels increased at both 6 and 12 h (Figure 4.13C) which was in
agreement with the qRT-PCR results (Figure 4.11A). These results suggest that
increase in JNK activation and c-Jun expression could both contribute to the
observed increase in c-Jun phosphorylation.

64

Phosphorylation of c-Jun is associated with transcriptional activation of
AP-1101 (Figure 4.10). We therefore then performed an AP-1 luciferase assay to
determine if WFA-induced increase in c-Jun and FosB in MDS-L cells had a
functional consequence on the transcriptional activity of AP-1. MDS-L cells
transfected with either the AP-1 reporter or empty vector expressing firefly
luciferase were treated with WFA for 12 h and promoter activity was assessed by
the dual Glo luciferase assay. The known activator of AP-1, PMA, was used as a
positive control for luciferase assays147. Cells were co-transfected with a control
vector expression renilla luciferase under the control of a constitutively active
thymidine kinase promoter. WFA potently induced AP-1 luciferase expression
(Figure 4.14A). These data were expanded by demonstrating transcriptional
activity of AP-1 even further by showing that WFA increased mRNA expression
of BIM (BCL2L12) (Figure 4.14B) and p21 (Figure 4.14C), both of which are bona
fide AP-1 targets85,111,112.
4d) WFA arrested MDS-L cells at S and G2/M cell cycle phases
p21 is a well-known negative regulator of cell cycle progression107.
Therefore, the increase in p21 expression following WFA treatment (Figure
4.14C) suggested that WFA might cause cell cycle arrest of MDS-L cells.
Moreover, WFA has been shown to induce cell cycle arrest of several other types
of cancer cells44,45. Hence, we asked if WFA treatment had an effect on the
cycling of MDS-L cells. Cell cycle analysis by flow cytometry showed WFA
indeed caused MDS-L cells to arrest at both S and G2/M phases (Figure 4.15).
Consistent with cell cycle analysis data, treatment with WFA significantly
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decreased mRNA and protein levels of the cyclins and CDKs required for
completion of both S (cyclin A and CDK2) (Figure 4.16A-C) and G2/M (cyclin B
and CDK1) (Figure 4.17A-C) phases of the cell cycle. The observed decreases in
expression of these cyclins and Cdks could likely be explained by increased
expression of p21 (Figure 4.14C). Even though p21 inhibits cell cycle progression
primarily by inhibiting the activities of CDK1 and CDK2, it has also been shown to
be involved in transcriptional repression of several cell cycle genes including
cyclins and Cdks such as CDK1, CCNB1 and CCNA191,148,149. WFA-induced cell
cycle arrest could also contribute to apoptotic death of MDS-L cells since
prolonged arrest in S and G2/M phases eventually triggers apoptosis85.
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Figure 4.1: Cytotoxic effects of WFA in MDS-L cells are independent of NFκB activation
(A) MDS-L cells treated with 10 μM WFA or DMSO for 4 h were stained for the p65 subunit of NF-κB and nuclear and cytoplasmic distribution of NF-κB was
determined by fluorescence microscopy. A representative field is shown. (B)
Quantification of cells (> 200 cells) in several fields with nuclear and/ or
cytoplasmic p-65 in MDS-L cells treated with10 μM WFA or DMSO for 4 h. (C)
Nuclear and cytoplasmic protein fractions of cells treated with 10 μM WFA or
DMSO for 2 or 4 h were used for western blotting to examine the effect of WFA
treatment on nuclear translocation of the p65 subunit of NF-κB. Cytoplasmic (C)
or nuclear (N) p65 NF-κB was normalized to GAPDH or Hdac1 respectively and
densitometric ratios are shown. Data are representative of two independent
experiments.
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Figure 4.2: Biological functions and/ or diseases most significantly affected
by WFA treatment in MDS-L cells
Heatmap of differentially expressed genes (p<0.05) between control and 6 h
WFA treated samples (A) or 12 h WFA treated samples (B). The top fifteen
biological functions and /or diseases enriched in the data set identified by IPA are
shown. Genes that belong to a specific IPA biological function are clustered and
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represented by a colored square next to the heatmap. Color key legend
represents log2 normalized expression values ranging from low expression
(green) to high expression (red).
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Figure 4.3: Heatmap of top 20 WFA regulated genes by fold change
The top 10 elevated (top half) and repressed (bottom half) genes by WFA at 6 h
and 12 h arranged by fold change are shown.

72

73

Figure 4.4: Genes differentially regulated by WFA are linked to apoptosis
induction
Gene set enrichment analysis (GSEA) revealed enrichment of apoptosis related
genes by WFA treatment at both 6 h (A) and 12 h (B) compared to control.
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Figure 4.5: WFA decreased mitochondrial membrane potential in MDS-L
cells
MDS-L cells were treated with WFA (10 μM or 20 μM) for 8 h or FCCP (50 μM)
for 2 h. One μM JC-1 was added during the last 30 min of treatment and the
distribution of JC-1 aggregates (red) and monomeric JC-1 (green) was analyzed
by flow cytometry. (A) Representative overlays of JC-1 aggregates or monomers
by mean fluorescent intensity. 10 μM WFA caused a decrease in fluorescence of
JC-1 aggregates with a concomitant increase in JC-1 monomer fluorescence
(upper panel) and the effect was even more dramatic with 20 μM WFA treatment
(lower panel). (B) Results are shown as mean ratios ± SD of JC-1
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aggregates/monomers as a function of treatment (n = 3). *** = p<0.0005.
Representative data from one of several experiments with similar results are
shown.
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Figure 4.6: WFA stimulated activation of caspase-3
Whole cell lysates from control or WFA treated (6 h or 12 h) MDS-L cells were
used for immunoblotting. Protein expression of activated (cleaved caspase-3) or
total caspase-3 was normalized to GAPDH (loading control) expression and
densitometric ratios are shown. Results are representative of several
experiments.
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Figure 4.7: WFA induced apoptosis of MDS-L cells
Cells were treated with increasing concentration of WFA for 48 h and apoptosis
was measured by annexin-V and PI staining. (A) Panels show representative
flow cytometry profile for each WFA concentration used. (B) Graph shows
percentage of annexin-V positive cells at different doses of WFA presented as
mean ± SD (n = 3). Data from one of three independent experiments with similar
results are shown.
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Figure 4.8: Up-regulated mRNA expression of BAG3 in MDS-L cells treated
with WFA
qRT-PCR of BAG3 mRNA in cells treated with DMSO or WFA (6 h and 12 h).
Gene amplification was normalized to RPII expression and relative amplification
was determined by normalizing to DMSO control. ** = p<0.005, *** = p<0.0005.
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Figure 4.9: WFA increased mRNA but not protein expression of RGS2 or
p38 MAPK activation in MDS-L cells
(A) Total RNA isolated from cells treated with DMSO or WFA (6 h and 12 h) was
used to determine mRNA expression of RGS2 by qRT-PCR. Gene amplification
was normalized to RPII expression and relative amplification was determined by
normalizing to DMSO control. (B) Western blots showing the effect of WFA
treatment on p38 MAPK activation and RGS2 protein expression. GAPDH was
used as a loading control. Western blot analysis is representative of two
independent experiments. * = p<0.05, ** = p<0.005.
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Figure 4.10: Schematic representation of ROS mediated JNK/AP-1 signaling
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Figure 4.11: WFA enhanced mRNA expression of c-Jun and FosB
Total RNA was isolated from cells treated with DMSO or WFA (6 h and 12 h).
The RNA samples were analyzed by qRT-PCR for c-Jun (A) and FosB mRNA
levels(B) using human specific primers. Gene amplification was normalized to
RPII expression and relative amplification was determined by normalizing to
DMSO control. ** = p<0.005, *** = p<0.0005. Representative data of two
independent experiments are shown.
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Figure 4.12: WFA treatment increased ROS production in MDS-L cells
Representative flow cytometry profiles of ROS production in MDS-L cells by DCF
fluorescence (A, B). Increased ROS production in MDS-L cells exposed to 10 μM
WFA for 30 min (A). 4 h pretreatment with NAC before exposure to WFA
inhibited ROS production (B). Amount of ROS produced normalized to DMSO
control samples. Mean measurements ± SD of three separate samples are
shown (C). ** = p<0.005, *** = p<0.0005. Results are representative of several
experiments.
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Figure 4.13: JNK MAPK signaling cascade is activated by WFA in MDS-L
cells
Western blot analysis of P-MKK7 (A), P-JNK (B) and P-c-Jun (C) on cell lysates
of MDS-L cells treated with or without WFA (10 μM) for the indicated time-points.
Activated or phosphorylated protein expression was normalized to the respective
total protein expression. Total c-Jun expression was normalized to GAPDH which
was also used as a loading control. Relative protein expression was analyzed by
densitometry. The values shown are fold change protein expression with respect
to DMSO controls. Data are representative of at least two independent
experiments.
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Figure 4.14: WFA triggered AP-1 transcriptional activity in MDS-L cells
(A) MDS-L cells were co-transfected with either an AP-1 or empty firefly
luciferase expression vector and a renilla luciferase vector under the control of a
constitutive promoter (2:1). Transfected cells were treated with WFA (10 μM) or
PMA (30 ng/ml) for 12 h and promoter activity was assessed by the dual Glo
luciferase assay. Firefly luciferase activity relative to renilla luciferase activity is
shown. Data are presented as mean ± SD of triplicate cultures.
(B, C) Total RNA was isolated from cells treated with DMSO or WFA (6 h and 12
h). The RNA samples were analyzed by qRT-PCR for BIM (B) or p21 (C)
expression using human specific primers. Gene amplification was normalized to
RPII expression and relative amplification was determined by normalizing to
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DMSO control. ** = p<0.005, *** = p<0.0005. Results from one of at least two
similar experiments are shown.
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Figure 4.15: Induction of cell cycle arrest in WFA-treated MDS-L cells
Cells were treated with the indicated concentrations of WFA for 48 h and stained
with PI. Intensity of PI staining which correlates with DNA content was analyzed
by flow cytometry. The fraction of cells (%) at each phase is shown. Data are
presented as mean ± SD from triplicate cultures. * = p<0.05, ** = p<0.005, *** =
p<0.0005; denotes significant differences in G, S and G2/M fractions between
cultures with and without WFA. Data shown are representative of three
experiments.
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Figure 4.16: mRNA and protein expression of cyclin A and CDK2 decrease
with WFA treatment
Total RNA samples isolated from cells treated with DMSO or WFA (6 h and 12 h
were analyzed by qRT-PCR for cyclin A (A) and CDK2 (B) expression using
human specific primers. Gene amplification was normalized to RPII expression
and relative amplification was determined by normalizing to DMSO control.
(C) Whole cell lysates from control or WFA treated (6 h or 12 h) MDS-L cells
were analyzed by immunoblotting for cyclin A and CDK2 protein expression.
Band intensities were normalized to GAPDH and are expressed as densitometric
ratios. * = p<0.05, *** = p<0.0005. Results from one of two experiments with
similar results are shown.
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Figure 4.17: mRNA and protein expression of cyclin B and CDK1 decrease
with WFA treatment
Total RNA samples isolated from cells treated with DMSO or WFA (6 h and 12
were analyzed by qRT-PCR for cyclin B (A) and CDK1 (B) expression using
human specific primers. Gene amplification was normalized to RPII expression
and relative amplification was determined by normalizing to DMSO control.
(C) Whole cell lysates from control or WFA treated (6 h or 12 h) MDS-L cells
were analyzed by immunoblotting for cyclin B and CDK1 protein expression.
Relative expression to β-actin is indicated by band intensity ratios. *** =
p<0.0005. Results from one of two similar experiments are shown.
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Summary
We performed microarray gene expression analysis to identify the molecular
mechanisms mediating WFA-induced cytotoxicity of MDS-L cells. Analysis of the
differentially expressed genes revealed that WFA significantly regulated genes
linked to apoptosis. The substantial increase in gene expression of AP-1
transcription factor subunits (c-Jun and FosB) suggested that WFA activated
JNK/AP-1 signaling. We used a combination of biochemical techniques to
validate the microarray data. Our results demonstrated that WFA caused
apoptosis and activated JNK/AP-1 signaling in MDS-L cells. In depth
investigation of AP-1 transcriptional activity induced by WFA treatment revealed
increased transcription of p21, an AP-1 target and cell cycle inhibitor. This finding
prompted us to test the effect of WFA on MDS-L cell cycle progression leading to
the observation that WFA inhibited cycling of MDS-L cells by arresting them at S
and G2/M cell cycle phases. This observation suggests that in addition to direct
increase in pro-apoptotic factors such as BIM, cell cycle inhibition could
potentially contribute to WFA-triggered MDS-L since prolonged arrest in S and
G2/M phases eventually triggers apoptosis85.
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CHAPTER FIVE
Selective WFA-induced cytotoxicity to MDS-L cells is primarily mediated by
increased ROS production
After confirming that WFA treatment triggered apoptotic cell death and
activated the JNK MAPK cascade in MDS-L cells, we sought to determine if the
observed apoptotic cell death was by JNK signaling. We explored this possibility
by determining the consequence of pharmacologically inhibiting JNK signaling in
WFA-treated cells on apoptosis.
5a) JNK signaling plays a significant role in WFA apoptosis of MDS-L cells by
WFA treatment
To determine if JNK signaling played a critical role in WFA-induced
apoptosis of MDS-L cells, we investigated the effect of pretreating cells for 4 h
with JNK-IN-8, a well characterized JNK inhibitor, on the level of caspase-3
activation by WFA. JNK-IN-8 is a potent and selective covalent JNK inhibitor
directed to the ATP-site that was first described in 2012150. Western blot analysis
showed that pretreatment with JNK-IN-8 reduced phosphorylation of c-JUN
induced by WFA, an excellent measure of JNK activation (Figure 5.1). JNK
inhibition led to an expected decrease in AP-1 transcriptional activity, shown by a
significant decrease in transcription of two well-known AP-1 targets, BIM (Figure
5.2A, B) and p21 (Figure 5.3A, B). Consistent with the crucial role of BIM in
regulating apoptosis, inhibition of JNK signaling by JNK-IN-8 blocked caspase-3
activation by WFA (Figure 5.4A, B).
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Off-target effects are always a concern with the use of small-molecule
inhibitors in biological systems. We therefore employed a second widely used
JNK inhibitor, SP600125, to verify our results demonstrating the critical role of
JNK signaling in WFA-activated apoptosis. Similar results with a second inhibitor
would further argue against the possibility that the phenotype observed with JNKIN-8 was due to off-target effects, since SP600125, a reversible ATP-competitive
JNK inhibitor151, is likely to have a different spectrum of off-targets. We verified
inhibition of JNK by SP600125 by showing that it reduced WFA-induced
phosphorylation of c-JUN (Figure 5.5A, B). Pretreatment of MDS-L cells with
SP600125 also suppressed caspase-3 activation caused by WFA treatment
(Figure 5.6A, B).
5b) WFA activated JNK signaling by increasing ROS production
We had demonstrated that WFA activated the ROS sensitive MAP3K
(ASK1) of the JNK cascade by increased phosphorylation of its target kinase,
MKK7 (Figure 4.13A). Hence, we hypothesized that WFA activated JNK/AP-1
signaling and apoptosis in MDS-L cells by increasing ROS production. We tested
this hypothesis by investigating the effect of pretreatment with 25 mM NAC, a
well-known antioxidant, on WFA-induced JNK/AP-1 activation and apoptosis.
Pretreatment with NAC significantly inhibited WFA-mediated JNK activation
compared to the no pretreatment control (Figure 5.7A, B). This inhibition
traversed downstream of the JNK cascade as NAC pretreatment also
substantially inhibited c-Jun phosphorylation (5.8A, B). In addition, NAC robustly
inhibited WFA-induced AP-1 transcription demonstrated by both AP-1 driven
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luciferase activity (Figure 5.9) and measurement of BIM (Figure 5.10A, B) and
p21 (Figure 5.11A, B) transcripts. Inhibition of AP-1 transcription complimented
the observed decrease in c-Jun phosphorylation with NAC pretreatment (Figure
5.8). Consistent with the concept of ROS-mediated JNK activation promoting
apoptosis in MDS-L cells, NAC pretreatment remarkably abrogated activation of
caspase-3 in these cells (5.12A). These results indicated that JNK/AP-1
activation and apoptosis in WFA treated cells was largely due to increased ROS
production.
5c) Inhibition of ROS production completely protected MDS-L cells from
cytotoxicity by WFA treatment
The significant role of ROS and JNK signaling activation in apoptotic cell
death of MDS-L cells treated with WFA was further demonstrated using the
annexin-V apoptosis assay. Inhibition of JNK signaling with JNK-IN-8 significantly
reduced WFA-induced apoptosis of MDS-L cells (Figure 5.13A, B). On the other
hand, NAC pretreatment completely protected MDS-L cells from apoptosis
caused by WFA treatment (Figure 5.13A, B). These results demonstrated that
not only was ROS upstream of JNK/AP-1 signaling activation (Figure 5.7-5.12), it
was the predominant mediator by which WFA caused apoptosis in MDS-L cells.
Of note, WFA failed to increase ROS in normal human primary bone marrow
cells (Figure 5.14) which were shown previously (Figure 3.10) to be resistant to
WFA-induced cell death. Hence, ROS production could explain why WFA was
selectively cytotoxic to MDS-L cells but spared normal bone marrow cells in vitro
and in vivo (Figures 3.6, 3.7, 3.8 and 3.10).
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Figure 5.1: JNK-IN-8 effectively inhibits JNK activation by WFA
Immunoblot analysis of P-c-Jun, total c-Jun and GAPDH (loading control) in
MDS-L cells treated with WFA for the indicated time-points after no pretreatment
or pretreatment with JNK-IN-8 (10 μM) for 4 h. P-c-Jun expression is presented
relative to total c-Jun.
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Figure 5.2: Inhibition of JNK activity suppresses transcription of BIM
induced by WFA
MDS-L cells were pretreated with or without JNK-IN-8 (10 μM) for 4 h. Total
RNA isolated from pretreated cells exposed to WFA for 6 h (A) or 12 h (B) was
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used to determine BIM expression by qRT-PCR. BIM amplification was
normalized to RPII and relative expression was determined by normalizing to
DMSO control. * = p<0.05, ** = p<0.005, *** = p<0.0005.
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Figure 5.3: JNK activation contributes to p21 transcription in WFA-treated
MDS-L cells
qRT-PCR analysis of p21 in MDS-L cells with or without JNK inhibition, treated
with WFA for 6 h (A) or 12 h (B). p21 amplication was normalized to the RPII
control gene and the results are presented relative to those of DMSO controls. **
= p<0.005, *** = p<0.0005.
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Figure 5.4: JNK-IN-8 substantially abrogates caspase-3 activation induced
by WFA in MDS-L cells
(A) Western blots showing active caspase-3 (cleaved caspase-3) and GAPDH
levels in MDS-L cells treated with WFA for 2, 6 or 12 h, with or without JNK
blockade by JNK-IN-8. (B) Relative cleaved caspase-3 expression in (A) was
normalized to GAPDH and the values expressed as densitometric ratios are
shown by a bar graph.
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Figure 5.5: SP600125 inhibits WFA-induced JNK activity
MDS-L cells pretreated with SP600125 (40 μM) for 4 h or without pretreatment
were exposed to WFA for an additional 0.25, 0.5, 1, 2, 6, or 12 h. The effect of
SP600125 treatment on JNK activity was assessed by immunoblotting for P-cJun (A). Bar graph representation of P-c-Jun expression in (A) normalized to total
c-Jun and WFA negative control (B).

109

Figure 5.6: SP600125 suppresses activation of caspase-3 by WFA
MDS-L cells with or without SP600125 (40 μM) treatment for 4 h, were treated
further with WFA for 2, 6, or 12 h. Whole cell lysates from treated cells were used
for immunoblot analysis of cleaved caspase-3 and β-actin (A). Cleaved caspase3 band intensities were normalized to β-actin and relative expression by
densitometric ratios is presented graphically (B).
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Figure 5.7: WFA-induced JNK activation is inhibited by NAC
Western blot analysis showing the effect of ROS blockade by NAC (25 mM)
pretreatment for 4 h on WFA-induced JNK activation in MDS-L cells at the
indicated time points (A). P-JNK expression in (A) expressed as a ratio to total
JNK, with WFA negative controls set as 1 (B).
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Figure 5.8: NAC inhibits JNK activity in WFA-treated MDS-L cells
(A) P-c-Jun levels measured by immunoblotting of WFA-treated MDS-L cells with
or without ROS blockade by NAC (25 mM) pretreatment for 4 h. (B) P-c-Jun band
intensities were normalized to those of total c-Jun and densitometric ratios of
WFA negative controls set to 1.
112

Figure 5.9: WFA-induced AP-1 dependent transcription is inhibited by NAC
MDS-L cells pretreated with or without NAC (25 mM) for 4 h were co-transfected
with an AP-1 firefly luciferase expression vector and a renilla luciferase vector
under the control of a constitutive promoter (2:1). Transfected cells were treated
with WFA (10 μM) for 12 h and promoter activity was assessed by the dual Glo
luciferase assay. The ratios of firefly to renilla luciferase activity in relative light
units are shown. Data are presented as mean ± SD of triplicate cultures. *** =
p<0.0005.
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Figure 5.10: Inhibition of ROS blocked BIM transcription in WFA-treated
MDS-L cells
BIM expression by qRT-PCR in MDS-L cells with or without ROS inhibition,
treated with WFA for 6 h (A) or 12 h (B). BIM expression was normalized to RPII
expression and the results are presented relative DMSO controls. * = p<0.05, ***
= p<0.0005.

115

116

Figure 5.11: NAC abrogated WFA-induced p21 transcription
MDS-L cells were pretreated with or without NAC (25 mM) for 4 h. Total RNA
isolated from pretreated cells exposed to WFA for 6 h (A) or 12 h (B) was used to
determine p21 expression by qRT-PCR. p21 amplification was normalized to
RPII and relative expression was determined by normalizing to DMSO control. ***
= p<0.0005.
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Figure 5.12: ROS inhibition completely abolished WFA-induced caspase-3
activation
Western blotting showing the effect of inhbiting ROS accumulation by NAC (25
mM) pretreatment for 4 h on WFA-induced caspase-3 activation in MDS-L cells
at the indicated time points.
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Figure 5.13: NAC protects MDS-L cells from apoptosis by WFA treatment
No pretreatment or pretreated (JNK-IN-8 or NAC for 4 h) MDS-L cells were
treated with WFA (10 μM) for an additional 24 h and stained with annexin-V and
PI. (A) Representative flow cytometry profiles of annexin-V/PI staining. (B)
Frequency of annexin-V positive cells. Data presented as mean ± SD (n = 3). ***
= p<0.0005.

120

Figure 5.14: WFA does not increase ROS in normal human primary bone
marrow cells
DCFH-DA assay by flow cytometry in normal human primary bone marrow cells
treated with WFA or H2O2 for 30 min.
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Summary
We previously demonstrated that WFA-induced ROS activated JNK/AP-1
signaling and apoptosis in MDS-L cells (chapter 4). Published studies have
shown that JNK/AP-1 activation can lead to apoptosis in many cell types93.
Therefore, we investigated the significance of JNK/AP-1 activation and increased
ROS production in MDS-L apoptosis by WFA. Pharmacological inhibition of JNK
by JNK-IN-8 or SP600125 in WFA treated cells revealed that JNK signaling
significantly contributes to WFA-induced apoptosis. We found that ROS was
upstream of JNK/AP-1 activation and apoptosis in MDS-L cells, since inhibition of
ROS with NAC inhibited both JNK/AP-1 signaling and apoptosis. Although
JNK/AP-1 signaling plays a significant role in WFA-induced apoptosis of MDS-L
cells, it was not the only pathway activated downstream of ROS because JNK
inhibition significantly reduced but did not prevent apoptosis. However, ROS
blockade completely prevented MDS-L apoptosis by WFA, suggesting ROS was
the predorminant mediator of MDS-L cytoxicity. Consistent with these findings,
WFA was not cytotoxic to normal human primary bone marrow cells in which
WFA did not increase ROS levels
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CHAPTER SIX
Discussion
There are three FDA approved drugs for MDS treatment, Lenalidomide,
azacitidine and decitabine27. Of these three, both azacitidine and decitabine are
hypomethlating agents29. Azacitidine and its derivative decitabine mediate DNA
demethylation by inactivating the DNA methylation enzyme, DNA
methyltransferase-1 (DNMT-1)29. Given that mutations in DNA methylation
(DNMT3A, TET2, IDH1/2), are recurrent in MDS9, it seems fitting that some MDS
patients respond to hypomethylating agents. However, the response rate to
these therapies is low and transient27. Only about 50% of MDS patients respond
to hypomethylating agents and a majority of responders relapse within 2-3
years27,29. The outcome of MDS patients after hypomethylating therapy failure is
very poor; - median overall survival and 2-year survival probability of 5.6 months
and 15%, respectively, have been reported152. The mechanism of action of
lenalidomide in MDS is not completely understood. Although it is generally
thought to be an immunomodulatary agent, lenalidomide-dependent modulation
of the CRL4CRBN E3 ubiquitin ligase substrate specificity is critical for the activity
of lenalidomide in del(5q) MDS134,153. Haploinsufficiency of csnk1a1 in
hematopoietic stem cells causes an in increase in β-catenin levels and survival
advantage while a homozygous loss of csnk1a1 causes p53 accumulation and
ablation of hematopoietic stem cells by apoptotic cell death154. Therefore,
targeted degradation by lenalidomide of casein kinase 1A1 (CK1α) in del(5q)
cells which are haploinsufficient in CK1α expression induces p53-mediated cell123

cycle arrest and cell death153. As with hypomethylating agents, the response of
MDS patients to lenalidomide is often not durable30,134. The incidence of relapse
with current FDA approved MDS therapies suggests these drugs are likely not
targeting the disease initiating clone. HSCT is a potentially curative MDS
treatment but the use of HSCT treatment for MDS is very limited31,32. Less than
10% of MDS patients are referred to HSCT31. Underuse of HSCT treatment for
MDS may be because MDS most commonly occurs in older adults and
comorbidities in older patients limit tolerance to the intensive preconditioning
HSCT treatments3,31,33. Given the current status of MDS treatment, there is is a
compelling need to investigate new therapies for MDS treatment.
Toxicity is a major problem with most of the established chemotherapy
drugs routinely used for cancer treatment36. Hence, scientific exploration of plantderived compounds for cancer treatment is on the rise because they are
considered to have less toxic side effects36,37. Withaferin A (WFA) is a plantderived compound that has been shown to have potential in anticancer
treatment39. The anticancer activities of WFA have been demonstrated in several
cancer models including prostate, breast, cervical and pancreatic cancers, as
well as melanoma and lymphoma44,45. The goal of this study was to determine if
the anticancer effects of WFA extend to MDS.
Although several MDS mouse models have been developed, the
heterogeneity of the disease has made it difficult to generate a mouse that
models complete disease phenotype133. The NUP98-HOXD13 fusion gene
transgenic mouse is one of the best of the reported MDS mouse models because
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it recapitulates a majority of MDS phenotypes including peripheral cytopenias,
dysplastic cell morphology and progression to AML155. Nonetheless, a majority of
the mice die rather from precursor T or B-cell lymphoblastic lymphoma/leukemia
and not MDS155. Xenotransplantation of primary MDS cells has been a challenge
because engraftment of primary MDS cells into immunocompromised mice is
poor and highly inefficient125,126. In the present study, we utilized the MDS-L cell
line model to investigate the anticancer potential and possible underlying
molecular mechanisms of action of WFA in MDS. MDS-L cells represent a highly
aggressive form of the disease because they have deletions in chromosomes 5
and 7127. Deletions in chromosomes 5 and 7 are not just the most common
cytogenetic abnormalities observed in MDS, but they have also been associated
with a significantly worse prognosis12,14,16,17. Even though the efficiency was
highly variable, the engraftment of MDS-L cells in NSGS mice was reproducible.
We found that WFA significantly inhibited the proliferation of MDS-L cells
both in vitro and in vivo. Similarly, WFA caused apoptosis of bone marrow cells
from patients with MDS or AML which validated the clinical relevance of this
study. Our findings also identified ROS signaling as a potential therapeutic target
that could selectively eliminate malignant MDS cells while sparing normal cells.
Importanlytly, WFA did not significantly change ROS levels in primary human
bone marrow cells, consistent with their resistance to WFA-induced cytoxicity.
We therefore propose ROS signaling as a potential therapuetic target that could
selectively target malignant MDS cells while sparing normal cells.
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6a) Molecular mechanisms mediating apoptosis of MDS-L cells by WFA
The anticancer activities of WFA have been studied in several cancer
models but the molecular mechanisms mediating these activities are not clearly
understood. Several pathways and molecules have been implicated in the
mechanism of action of WFA in cancer cells, including NF-κB, Akt, Stat3, ER-α,
endoplasmic reticulum (ER) stress response, ROS, and MAP kinases (p38, ERK
and JNK)44. It is now becoming clear that although WFA can target multiple
pathways, certain pathways could be cell type specific44,50. Our finding that the
mechanism(s) mediating growth inhibitory effects of WFA in MDS-L cells are NFκB independent (Figure 4.1) support the idea of cell type specific mechanisms
induced by WFA. To understand the pathways mediating cell death in MDS-L
cells treated with WFA, we performed microarray gene expression analyses on
cells treated with WFA or DMSO. Analyses of the microarray data led us to the
identify JNK/AP-1 signaling as one of the major pathways mediating WFAinduced apoptosis of MDS-L cells. Functional analysis of the differentially
expressed genes revealed WFA induced cell death by apoptosis. Induction of
apoptosis by WFA in MDS-L cells was confirmed by a decrease in MMP,
activation of caspase-3 and an increase in the frequency of annexin-V positive
cells with WFA treatment. A closer look at the top differentially regulated genes
revealed c-Jun and FosB were substantially induced by WFA; 47- and 52- fold at
6 and 12 h respectively for c-Jun while FosB was up-regulated 36-fold at 6 h and
60-fold at 12 h. We focused on c-Jun and FosB because they can heterodimerize
to form an AP-1 transcription factor that is activated by phosphorylation of the c126

Jun subunit by JNK and, JNK/AP-1 signaling has been demonstrated to regulate
apoptosis93,101. In addition, JNK cascade activation can be mediated by the ROS
sensitive ASK1 and increased ROS production is one of the reported
mechanisms by which WFA exerts anticancer effects49,62-66,98,108. WFA treatment
increased ROS and activated JNK/AP-1 signaling in MDS-L cells. Activated or
phosphorylated JNK can promote apoptosis indirectly by mediating AP-1 induced
expression of pro-apoptotic proteins like BIM111,112. BIM induces Bax and Bad
activation by inhibiting pro-apoptotic proteins such as Bcl-2 and Mcl-1, resulting
in increased mitochondrial permeability and apoptosis156. Our data showed that
WFA induced BIM expression in MDS-L cells and we also observed a substantial
decrease in MMP with WFA treatment in MDS-L cells. These results indicate that
increase in BIM expression by JNK/AP-1 signaling mediates apoptosis of MDS-L
cells treated with WFA. It is known that sustained p21 expression leads to cell
cycle arrest and apoptosis85. We also found that WFA induced JNK/AP-1
dependent expression of p21 and cell cycle arrest in MDS-L cells. Therefore, it is
probable that cell cycle arrest by JNK/AP-1 control of p21 transcription also
contributes to apoptosis of MDS-L cells by WFA.
Our studies demonstrated that increased ROS production by WFA in
MDS-L cells activated JNK/AP-1 signaling and apoptosis by showing that ROS
inhibition abrogated JNK/AP-1 signaling and completely protected MDS-L cells
from WFA-induced apoptosis. However, JNK signaling is not the only major
pathway activated by increased ROS that mediates apoptosis of MDS-L cells
treated with WFA. This is because while we could completely abrogate WFA127

induced apoptosis of MDS-L cells by inhibiting ROS, inhibition of JNK
significantly reduced (p<0.0005) but did not completely prevent WFA-induced
apoptosis of MDS-L cells. The incomplete protection by JNK inhibition by JNK
inhibitors could be due to their cross-reactivity with other kinases important for
cell survival. Alternatively, ROS may induce pathway(s) other than JNK that
mediate apoptosis.
ROS-induced cell cycle arrest is a plausible simultaneous pathway that
could promote apoptosis in parallel with JNK signaling. It is known that ROSinduced DNA damage results in cell cycle arrest85. Cell cycle arrest allows for
DNA damage repair but apoptosis is triggered if repair fails or is overwhelmed by
too many DNA lesions157. We observed induction of cell cycle arrest in MDS-L
cells treated with WFA. Although increased expression of p21 by AP-1 via JNK
activation can explain the observed cell cycle arrest, we cannot rule out a
contribution from DNA damage mediated cell cycle arrest pathways. ROSmediated DNA damage was not demonstrated in this present study but WFA has
been previously shown to induce ROS-mediated DNA damage158. Additionally,
IPA analysis of our microarray data revealed p53 was one of the upstream
regulators activated by WFA (P = 7.58E-22 at 6 h and P = 1.81E-18 at 12 h).
Apoptosis is a secondary response after DNA damage. Hence, we would infer a
longer kinetic for the apoptosis response triggered by prolonged cell cycle arrest.
This could explain why the substantial inhibition of caspase-3 activation by WFA
observed in JNK-IN-8 pretreated cells at 6 and 12 h did not strictly correlate with
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the frequency of annexin-V positive cells at 24 h. Inhibition of JNK would not
interfere with a ROS-induced DNA damage mediated apoptosis response.
6b) Oxidative stress is a feasible biochemical alteration that can be exploited for
selective treatment in MDS
A major goal in cancer therapy is to develop drugs that would more
selectively target malignant cells with minimum toxicity to normal cells. Toxic side
effects routinely observed with most established chemotherapy drugs could be
ameliorated by therapeutic selectivity36. The idea of exploiting cancer redox
biology as a basis for therapeutic selectivity is not a new concept159. Most cancer
cells have increased levels of ROS compared to their normal
counterparts117,160,161. Increased ROS levels have been associated with
oncogenic transformation, tumor progression and poor prognosis161-164. Redox
homeostasis is an essential delicate balance under normal physiological
conditions as excess ROS can result in apoptotic cell death108. An antioxidant
defense system has evolved to maintain ROS levels below the toxic threshold
beyond which cell death is induced72.
It used to be a conundrum why the increased oxidative stress was
insufficient to cause cell death in cancer cells. However, it is now appreciated
that cancer cells adapt to this increased oxidative stress by upregulating their
antioxidant capacity to keep them below the toxic threshold165-167. This adaptation
suggests a delicate redox balance is also required for cancer cell function and
tipping this balance may be a potential therapeutic strategy116,165-167. Cancer cells
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are more dependent than normal cells on the antioxidant system which would
make them more vulnerable to compounds that inhibit this system165,166.
Likewise, increased oxidative stress could put cancer cells closer to the toxic
threshold compared to their normal counterparts159. Therefore, a further increase
in ROS is likely to push cancer cells but not normal cells beyond the toxic
threshold159,165,166. Ovarian cancer, breast cancer and AML are examples of
cancer systems in which the potential of ROS inducing agents in cancer therapy
has been demonstrated65,124,161. The implication of increased oxidative stress in
the development and prognosis of MDS118 is an indication that ROS inducing
agents have a selective therapeutic potential in MDS.
6c) Model of cytotoxicity mechanisms of WFA in MDS
Based on our findings, we propose a model in which WFA increases ROS
in MDS-L cells to induce cell death primarily by apoptosis (Figure 6.1). This is
contrary to the report that WFA primarily induces autophagic cell death of MDS-L
cells55. However, it is noteworthy that the maximum drug concentration used in
that study was 1 µM compared to 10 µM for this study. The difference in outcome
with different WFA concentrations on the same cell line further supports the idea
of a ROS threshold requirement for ROS-induced apoptotic cell death.
Nevertheless, this possibility would have to be demonstrated experimentally for a
definitive conclusion. The mechanisms by which ROS inducing agents increase
ROS are unclear124. The mitochondrion is thought to be the main source of
intracellular ROS in eukaryotic cells168. Whether this is the site of ROS
production in MDS-L cells treated with WFA was not determined in this study.
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However, WFA has been shown to inhibit complex III activity within the
mitochondrial respiratory chain and this inhibition induces ROS production by
complex I and complex II49,169. This increase in ROS by WFA in MDS-L cells
results in the activation of ASK1 and subsequent activation of JNK via MKK7.
Activated JNK also allows for AP-1 dependent transcription of pro-apoptotic
proteins like BIM which promotes apoptosis by decreasing MMP. WFA-induced
ROS also mediates cell cycle arrest which could further promote apoptosis. All
pathways mediating apoptosis in MDS-L cells by WFA are ROS-dependent
because pre-incubation of cells with NAC prior to WFA treatment completely
prevented apoptosis. ROS and JNK have been shown, independently, to be
involved in the mechanisms mediating WFA cytotoxicity in other cancer cells44.
Our studies established a link between WFA-induced ROS, JNK/AP-1 signaling
and apoptosis in MDS-L cells. In addition, we demonstrated that increase in ROS
production is central to the cytotoxicity of WFA in MDS-L cells. Consequently, we
suggest redox biology could be exploited as the basis for therapeutic selectivity
in MDS.
6d) Conclusion
The study presented here demonstrates that the plant derived compound
WFA is a potential therapeutic agent for MDS treatment. Our results show that
increase in ROS is central to the apoptosis of MDS-L cells treated with WFA. We
identify redox biology as a potential avenue by which therapeutic selectivity can
be achieved in MDS. However, several unknowns still remain to be addressed:
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1. A pharmacokinetic evaluation of WFA in this study model is required to
determine the optimal dose in vivo. It has been reported that the plasma
concentration of WFA from a single IP injection of 4mg/kg in female BALB/c mice
is 1.8μM with a half-life of about 1.3 h170. Nonetheless, we recognize that this
was a single study and mouse strain and the purity of WFA used would impact
the pharmacokinetic profile.
2. Detailed analyses of the toxicity profile of WFA are also of utmost importance.
We monitored toxicity in this study by weight loss and found WFA to be generally
safe (Figure 3.7E). The GI tract is usually highly susceptible to
chemotherapeutics because the cells in the epithelium are highly proliferative. In
another study investigating the effects of WFA in a mouse lymphoma model, we
found that WFA had no apparent effect on the GI tract (data not shown). Another
important target of most chemotherapeutics is the bone marrow as bone marrow
suppression is a major side effect of most cancer therapies138. WFA did not
suppress endogenous stem cells in this study (Figure 3.8). In fact, it rather
stimulated an expansion of the stem cell population (Figure 3.8). However, the
effect of WFA on the clonogenenic and repopulation potential of these stem cells
has to be evaluated.
3. It is clear that WFA induces ROS in MDS-L cells but the mechanism and
species of ROS responsible for selective WFA toxicity remain unclear. The fact
that catalase has no effect on WFA-induced ROS (data not shown) suggests
H2O2 is not the ROS species of interest. This information will be useful to improve
the efficiency of WFA and/or identify more efficient ROS-inducing agents.
132

4. Because the ROS threshold concept likely underlies the therapeutic selectivity
of WFA in MDS, it is imperative to determine the optimal dose at which maximum
killing of malignant cells occurs without pushing normal cells beyond the toxic
threshold.
5. Efficacy of other ROS-inducing agents in MDS has to be evaluated.
Compounds such as 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD8), 3-deazaneplanocin A (DZNep), and dimethylaminoparthenolide (DMAPT),
which have already been demonstrated to cause killing of AML cells by inducing
ROS124 would be good candidates.
6. Combinatorial effects of WFA and current FDA approved therapies have to be
evaluated. Although combining WFA and lenalidomide was neither synergistic
nor additive in vitro, the in vivo outcome should be investigated. This is especially
so because lenalidomide, azacitidine and decitabine all induce an erythroid
response which cannot be evaluated in vitro.
7. We observed that the efficiency of engraftment of MDS-L cells in NSGS mice
was highly variable. Therefore, it will be important to explore methods of reducing
this variability such as intrafemoral injection of cells into mice and co-injection of
MDS-L cells with human derived stromal cell lines.
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Figure 6.1: Cytototoxicity mechanisms of WFA in MDS
WFA increases ROS in the cell which acitvates JNK/AP-1 signaling. Increased
ROS and expression of AP-1 target genes lead to cell cycle arrest and apoptosis.
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COMPOSITION OF POLYACRYLAMIDE GELS

STACKING GEL (5%)
STOCK SOLUTION

VOLUME (ml)

H2O

3

1M Tris pH 6.8

1.25

40% Acrylamide

0.63

10% SDS

0.05

10% APS

0.05

TEMED

0.0005

Total volume

4.985
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RESLOVING GEL
STOCK SOLUTION

VOLUME (ml)
9%

10%

12%

H2O

10.2

9.8

8.8

1M Tris pH 6.8

5

5

5

40% Acrylamide

4.5

5

6

10% SDS

0.2

0.2

0.2

10% APS

0.2

0.2

0.2

TEMED

0.02

0.02

0.02

Total volume

20.12

20.12

20.12
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APPENDIX C:
LIST OF ABBREVIATIONS
2-ME - 2-Mercaptoethanol
AML - Acute myeloid leukemia
AP-1 - Activator protein-1
APS - Ammonium persulfate
ASK1 - Apoptosis signal-regulating kinase 1
ATF2 - Activating transcription factor 2
BAG3 - Bcl2-associated athanogene 3
BCA - Bicinchoninic Acid
Carboxy-DCFDA - 5-(and-6)-Carboxy-2',7'-Dichlorofluorescein Diacetate
Carboxy-H2DCFDA - 6-Carboxy-2',7'-Dichlorodihydrofluorescein Diacetate
CAT - Catalase
Cdc25 - Cell division cycle 25
Cdks - Cyclin dependent kinases
CK1α - casein kinase 1A1
del 5q - Deletion in chormosome 5q
DLAR - Division of Laboratory Animal Resources
DMAPT - Dimethylaminoparthenolide
DMSO - Dimethyl sulfoxide
DNMT-1 - DNA methyltransferase-1
DZNep - 3-deazaneplanocin A
EDTA - Ethylenediaminetetraacetic acid
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ER - Endoplasmic reticulum
FACS - Fluorescence activated cell sorter
Fas-L - Fas-ligand
FBS - Fetal bovine serum
FCCP - Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
FDR - False discovery rate
FWER - Family-wise error rate
GPx - Glutathione peroxidase
GSH - Glutathione
GSSG - Glutathione disulfide
H2O2 - Hydrogen peroxide
HSCT - Hematopoietic stem cell transplant
Hsp90 - Heat shock protein 90
IACUC - Institutional Animal Care and Use Committee
IPA - Ingenuity Pathway Analysis
IR - Irradiation
JNKs - c-Jun N-terminal kinases
LENA - Lenalidomide
LSK - Lineage negative cells double positive for both Sca-1 and c-KIT
MAPK - Mitogen-activated protein kinase
MDS - Myelodysplastic syndromes
MMP - Mitochondrial membrane potential
MSigDB - Molecular Signature Database
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MTT - 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NAC - N-acetyl-cysteine
NADPH-oxidase - Nicotinamide adenine dinuleotide phosphate-oxidase
NCC - N-terminal coiled coil
NCI - National Cancer Institute
NSG - NOD/SCID-IL2Rγ
NSGS - NSG-hSCF/hGM-CSF/hIL3
OSU CCC - Ohio State University Comprehensive Cancer Center
PBS - Phosphate buffered saline
PI - Propidium Iodide
PMA - Phorbol 12-myristate-13-acetate
qRT-PCR - Quantitative Real-Time PCR
RGS-2 - Regulator of G-protein signaling 2
ROS - Reactive oxygen species
Sca-1 - Stem cell antigen
SDS - Sodium dodecyl sulfate
SOD - Superoxide dismutase
SP-1 - Specificity protein 1
TBST - Tris buffered saline Tween 20
TDZD-8 - 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione
t-MDS - Therapy-related myelodysplastic syndrome
Trx - Thioredoxin
WFA - Withaferin A
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WHO - World Health Organization
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